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INTRODUCTION 
Human immunodeficiency virus type 1 (HIV-1) is a causative agent of AIDS – 
a severe lifelong disease. Approximately 35 million people were living with 
HIV-1 and 1.5 million people died from HIV-1-related diseases in 2013 (WHO 
http://www.who.int/hiv/data/en/). There is no preventive (or therapeutic) vac-
cine for HIV-1. Repeated attempts to produce such a vaccine have either com-
pletely failed or, at best, have achieved marginal results. As there is no vaccine 
in use or even on the horizon, the treatment of HIV-1 relies on the use of antivi-
rals that can suppress its infection cycle. Over time, 28 different compounds 
have been licensed as anti-HIV drugs, and currently there are 23 compounds 
that have been approved by the Food and Drug Administration (FDA) for the 
treatment of HIV-1 infection/AIDS. Antiretroviral therapy (ART, also known as 
highly active antiretroviral therapy, or HAART) has been in use since the mid-
1990s and is based on the simultaneous use of a combination of at least 3 drugs 
with different modes of action (http://aidsinfo.nih.gov/contentfiles/ 
lvguidelines/AdultandAdolescentGL.pdf). Such treatment is effective but is life-
long. Furthermore, frequently, severe adverse effects and resistance to these 
compounds can be developed. As such, many laboratories around the world are 
seeking new compounds that are better than existing ones by several aspects: 
1. They are effective against wild type (wt) virus at lower concentrations. 
2. They are equally efficient against wt and known resistant forms of the virus 
and have higher genetic barriers against the development of resistance. 
3. They have lower toxicity (acting only on the virus and not on the organism). 
4. They have favorable pharmacokinetic characteristics, including i) good shelf 
life, enabling storage at room temperature, ii) possibility of administration in 
pill-form; and iii) stability in an organism for at least 24 hours, enabling 
once daily administration. 
5. They are cheaper to produce. 
 
To develop such compounds, chemical and biological laboratories should work 
together, which is the case in our Center of Excellence in Chemical Biology. 
The current thesis presents the results of collaboration between our (virology) 
laboratory and three different chemical laboratories. Together, we have studied 
the antiretroviral properties of acyclic thymine nucleoside analogues (article I), 
bimorpholines (article II), saccharide hydrazones (article III) and diaryltriazine 
derivatives (which were found during experimental validation of in silico 
screening; article IV), as well some other compounds (unpublished data).  
Thus far, the data presented in article IV represent the most successful 
attempt at developing an HIV-1 inhibitor that satisfies at least some of the 
requirements listed above. One of the studied compounds has an efficiency that 
is comparable to the known HIV-1 inhibitor nevirapine; however, similar to this 
commercial inhibitor, its activity was mostly restricted to wt virus (it did not 
work against known resistant forms). However, it was never expected that any 
of studied compounds would immediately become a new drug that can replace 
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or supplement the existing drugs on the market. Inventing a drug is a long and 
difficult process, and only a few out of many thousands reach the goal success-
fully. Finding compounds with new scaffolds and promising properties is often 
the first, and sometimes the most crucial, step in the direction leading to the 
discovery of new paths and methods of combating this remarkably flexible and 
difficult-to-counter virus. 
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LITERATURE REVIEW 
If the term “over-studied” could be applied to any virus, it would certainly be 
HIV-1, which is by far the most studied virus. As the number of papers pub-
lished on HIV-1 (around 270,000 by the summer of 2015) is roughly equal to 
the number of atoms in the HIV-1 genome, it is also very likely the most stud-
ied biological object as well. Unfortunately, this does not mean that we know all 
that there is to know about this virus. However, it does mean that the available 
literature is immense and full of repeats (the same thing discovered over and 
over again) and contradictions. Even the literature that is available on HIV-1 
inhibitors (well over 10,000 papers) is extremely massive. As it is beyond any-
one’s capacity to work through all of the data available on HIV-1, this review 
cannot deal with all of the known (or even all of the important) aspects of HIV-
1 biology. In many cases, preference was given to classical studies, especially 
when dealing with the basic properties of the virus and its replication; when 
discussing HIV inhibitors, the literature that seemed to be the most relevant 
(unfortunately, it is simply impossible to read all of the papers to determine 
which are truly the most relevant) has been reviewed. 
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1. VIRUS 
1.1 History of discovery 
HIV-1 infects humans, and the progression of its infection leads to AIDS. At the 
final stage of this disease, the immune system of an infected person becomes 
severely damaged; as a result, this person becomes susceptible to a number of 
opportunistic infections (typically rare in people with healthy immune systems) 
and eventually dies.  
Such symptoms were first described in homosexual men from the USA in 
1981 (Brennan and Durack, 1981; Friedman-Kien, 1981; Gottlieb et al., 1981; 
Siegal et al., 1981). The discovery of the causative agent of AIDS is the result 
of work carried out in two laboratories: Robert Gallo’s group in the USA and 
Luc Montagnier’s group in France. In 1983, Luc Montagnier’s group reported 
that a new retrovirus was isolated from patients with AIDS (Barré-Sinoussi et 
al., 1983); a year later, it was proved that this virus is the causative agent of 
AIDS (Levy et al., 1984; Popovic et al., 1984). Luc Montagnier and his col-
league Françoise Barré-Sinoussi were awarded the Nobel Prize in 2008 for their 
discovery of HIV-1. 
 
 
1.2 Origin and classification of HIV-1  
HIV-1 belongs to the family Retroviridae, genus Lentiviruses, group of primate 
lentiviruses. This group includes HIV-1 and HIV-2, as well as numerous simian 
immunodeficiency viruses (SIVs). SIVs infect around 40 species of nonhuman 
primates. Intriguingly, in their natural hosts, SIVs replicate successfully but do 
not cause a disease similar to AIDS, which most likely reflects long-term host-
viral coevolution (Apetrei et al., 2004). It is believed that HIVs were transmitted 
from monkeys to humans during hunting, meat-cutting or through the bites of 
domesticated animals.  
There are 2 different species of HIV: HIV-1 and HIV-2. Although they are 
very similar and the progression of the disease leads to nearly identical clinical 
pictures, some important differences still exist. HIV-1 is a pandemic virus and 
is the cause of most AIDS cases globally. HIV-2 is endemic and is mostly found 
in West Africa. Current research is focused on HIV-1, which will be discussed 
in the remainder of this work unless otherwise noted. 
It should also be noted that even HIV-1 is genetically heterogeneous. The 
major types of HIV-1, M, N, O and P, probably originated from different mon-
key (or, more accurately, ape) to human transmissions, which occurred around 
100 years ago. Of these, only type M has become pandemic, causing the vast 
majority of HIV-infections in the world. The M type of HIV-1 is also heteroge-
neous; the existing subtypes are referred to as clades (around 10 are known), 
which are divided into sub-subtypes. To add to the complexity, there are a num-
ber of recombinants between the clades that are also in circulation (termed cir-
culating recombinant forms or CRF’s). Clade (subtype) B is responsible for 
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most of the infections that occur in America, western Europe, Australia and 
Japan; not surprisingly, this clade has also been the main target of anti-HIV-1 
drug development. In eastern Europe, clade A is dominant. Surprisingly, Esto-
nia is an exception, as the HIV-1 epidemics that have occurred in this country 
have almost exclusively been caused by the rare CRF06_cpx virus and its 
recombinant with A-clade virus, which is termed CRF32_06A1 (Adojaan et al., 
2005; Avi et al., 2014). 
 
 
1.3 Structure of the mature HIV-1 virion 
HIV-1 is an enveloped virus with roughly spherical virions of variable size (its 
diameter is between 106 and 183 nm) (Figure 1) (Briggs et al., 2003, 2006). Its 
viral membrane is derived from the plasma membrane of the host cell and con-
tains HIV-1 envelope proteins and some cellular membrane proteins. There are 
2 viral envelope proteins, both originating from the cleavage of the same pre-
cursor (env protein): SU (surface protein, also known as gp120, which lies on 
the outer surface of the membrane) and TM (transmembrane protein, also 
known as gp41, which anchors SU to the viral membrane). SU and TM are 
heavily glycosylated; they bind to each other non-covalently and form hetero-
dimers. Three heterodimers cluster together to form mushroom-shaped trimers. 
In contrast to other retroviruses, HIV-1 particles contain very few (≈10, values 
between 4–35 have been reported) evenly distributed trimers (Zhu et al., 2003). 
Beneath the membrane, there is an incomplete layer of matrix protein (MA) 
(Briggs and Kräusslich, 2011).  
 
 
Figure 1. Structure of a mature HIV-1 virion. Clockwise from the left: PM – virion 
envelope derived from the plasma membrane of an infected cell, TM – transmembrane 
protein, SU – surface unit protein, MA – matrix protein, CA – capsid protein, NC – 
nucleocapsid protein, IN – integrase, PR – protease, RT – reverse transcriptase. 
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Inside the particle, there is a cone-like core structure. The shell of the core is 
formed by approximately 250 hexamers and exactly 12 pentamers of capsid 
protein (CA), which adopt fullerene-type geometry. Inside the core, there is a 
ribonucleoprotein (RNP) complex consisting of nucleocapsid protein (NC) and 
genomic RNA (there are 2 copies of RNA per virion). There are ≈5000 copies 
of each of MA, CA and NC protein and p6 peptide per particle. Importantly, the 
core also contains ≈250 copies of each of the essential viral enzymes: protease 
(PR), reverse transcriptase (RT) and integrase (IN).  
 
The HIV particle also contains some accessory proteins: virion infectivity fac-
tor, Vif (1–150 copies per particle); viral protein R, Vpr (≈700 copies per parti-
cle); and some amount of negative factor, Nef. The other accessory proteins 
(trans-activator of transcription, Tat; regulator of expression of virion proteins, 
Rev; and viral protein U, Vpu) that are encoded by the HIV-1 genome have not 
been found in the particle (Swanson and Malim, 2008; Turner and Summers, 
1999).  
HIV particles also incorporate a number of host cell proteins. Some of these 
proteins have no known role in viral replication and are presumably incorpo-
rated into the particle non-specifically (simply because they are located near the 
budding site of a virus). Other cellular proteins, however, are important for viral 
infectivity and life cycle. These latter proteins can be found either in the viral 
membrane (ICAM-1 (CD54), HLA-II) or inside of the particle (lysyl-tRNA 
synthetase, heat shock protein 70 (Hsp70), proteins of the actin cytoskeleton 
and some others) (see (Ott, 2008) for details). 
 
 
1.4 HIV-1 genome organization 
The viral genome is a single-stranded RNA of positive polarity; the same strand 
is also used as an mRNA for protein (gag-pro-pol) synthesis. It is about 9200 
nucleotides long and has a 5’ cap and a 3’ polyadenylated tail (Figure 2A). Each 
HIV-1 virion contains 2 copies of this RNA; they form a non-covalent dimer. 
HIV RNA has 9 open reading frames (ORFs) that encode 15 mature proteins 
(Frankel and Young, 1998) (Figure 2C).  
HIV RNA contains a number of important regulatory sequences (Berkhout, 
1996; Watts et al., 2009): 
1. The R (redundant) region. There are 2 identical R regions at each end of the 
viral RNA genome, and they play an important role in reverse transcription 
(during the first-strand transfer reaction; see below). The R regions contain 
TAR hairpin and poly(A) hairpin elements. 
2. The TAR hairpin. The trans-acting responsive element binds viral (tat) and 
cellular proteins and is involved in the regulation of transcription. As it is a 
part of the R-element, there are 2 copies of TAR per genome; however, only 
the element at the 5’-end of the genome is functional. 
17 
 
3. The poly(A) hairpin. This element contains a polyadenylation signal. Again, 
there are 2 copies of it per genome. In the case of this element, only the 
poly(A) hairpin that is located at the 3’-end of the genome is active. 
4. The U5 region. This region is unique to the 5’-end of the genome. It contains 
an att site, which is important for the integration of viral cDNA into the host 
genome. 
5. The primer-binding site (PBS). This element is complementary to the 3’-end 
of tRNALys3, which acts as a primer for HIV-1 reverse transcriptase. 
6. The dimerization initiation signal (DIS). This element contains a palin-
dromic sequence and is the site where the dimerization of 2 genomic RNAs 
begins. 
7. The RNA packaging signal (ψ). This element is involved in genome packag-
ing (some other sequences participate in this process as well). 
8. The polypurine tracts. There are two PPTs with identical sequences in the 
HIV-1 genome: a central PPT (cPPT) and a PPT close to the 3’-end  
(3’ PPT). Both of these elements serve as primers for plus-strand DNA  
synthesis. 
9. The U3 region. This region is unique to the 3’-end of the genome. It contains 
a second att site, which is important for the integration of viral cDNA into 
the host genome, as well as the majority of sequences that regulate the gene 
expression of HIV-1 provirus (see below). 
 
 
 
Figure 2. Cis-acting elements in HIV-1 genomic RNA (A) and in proviral DNA (B). 
(C) Organization of the coding regions inside of the HIV-1 provirus.  
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During the process of reverse transcription, viral RNA is copied into viral 
cDNA, which has long terminal repeats (LTRs) at both ends (Figure 2B). The 
LTRs are 2 identical sequences, each consisting of U3, R and U5 regions. They 
are important for the integration of viral cDNA into the host genome and for 
subsequent synthesis of viral RNAs. 
 
 
1.5 HIV-1 infection cycle 
1.5.1 Cell binding and entry 
Binding and entry into the host cell is the first step of the HIV-1 replication 
cycle. It begins with viral attachment to the host cell and results in a fusion of 
virion envelope with cellular membrane, leading to the delivery of the viral core 
inside the cell (Wilen et al., 2012). This process is complex and can be divided 
into several phases: 
1. Nonspecific binding to the cell via attachment factors. The attachment 
factors bind to the HIV-1 virion, but they are not essential for infection (in 
contrast to viral receptors) (Connell and Lortat-Jacob, 2013; Friedrich et al., 
2011; Geijtenbeek et al., 2000; Ugolini et al., 1999). 
2. Specific binding of the viral envelope complex to its cellular receptor CD4. 
This interaction induces conformational changes in SU, exposing the binding 
site for the HIV-1 co-receptor. 
3. Transfer of bound virion along the host plasma membrane to the sites where 
HIV-1 co-receptors are located. 
4. Co-receptor binding. Virions can bind one of the two HIV-1 co-receptors, 
the chemokine receptors CCR5 and CXCR4. HIV-1 strains are classified 
based on their co-receptor usage. R5 HIV-1 can use only CCR5, X4 HIV-1 
can use only CXCR4, and R5X4 HIV-1 can use both CCR5 and CXCR4.  
5. Membrane fusion. Co-receptor binding triggers further conformational 
changes in the envelope protein. This leads to the exposure of the 
hydrophobic fusion peptide of TM, which inserts itself into the cellular 
membrane. This, in turn, triggers rearrangements in TM trimers, and as 
result a six-helix hairpin structure is formed, bringing the viral and cellular 
membranes into close proximity and resulting in the formation of the fusion 
pore (Blumenthal et al., 2012). 
Subsequently the pore dilates to create an opening wide enough (≈50 nm) 
for the viral core to enter the cytoplasm. This is a very energy-demanding 
step, and some cellular processes (cell signaling and actin rearrangements) 
are potentially involved in it (Blumenthal et al., 2012). 
 
 
1.5.2 Early post-entry events 
After the virion core structure enters the cell, the virus must synthesize its 
cDNA, transport it to the nucleus and achieve its integration into the host  
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genome. The initial events of reverse transcription (synthesis of viral cDNA on 
the template of genomic RNA) sometimes can start in the core of the intact 
particle (Lori et al., 1992; Trono, 1992). In the cytoplasm the core is gradually 
transformed into the RTC (reverse transcription complex), where reverse 
transcription continues. The RTC travels across the cell using microtubule-
directed transport, and in the perinuclear area its movement is actin-directed 
(Arhel et al., 2006; McDonald et al., 2002). During maturation, the RTC 
enlarges (100 nm wide and 400–700 nm in length, different shape) (McDonald 
et al., 2002), loses some viral proteins (the capsid protein is removed in a highly 
regulated “uncoating” process; most of the reverse transcriptase and Nef are 
lost) and acquires some cellular proteins (Fassati and Goff, 2001; Iordanskiy et 
al., 2006; Nermut and Fassati, 2003). When DNA synthesis is complete, the PIC 
(pre-integration complex) is formed, which is transported to the nucleus through 
the nuclear pore. A detailed description of the replication process and the 
involved enzymes is given in the subsequent sections. 
 
 
1.5.3 HIV-1 cDNA integration 
For successful replication to occur, a product of reverse transcription, viral 
cDNA, must be integrated into the genome of the host cell (for review, see 
(Craigie and Bushman, 2012)). Integrated viral cDNA is called provirus and 
serves as a template for the synthesis of viral RNAs. The integration reaction 
requires the presence of integrase (IN), a viral enzyme that is present in the 
infecting viral particle, which enters the cell in the virion core and is thus a part 
of the RTC and PIC. IN is a tetramer (dimer of dimers) that is complexed in the 
PIC with the ends of newly synthesized viral cDNA. The integration reaction is 
performed in basic 3 steps (Brown et al., 1989; Fujiwara and Mizuuchi, 1988): 
1. 3’ end processing. IN cuts off the last 2 nucleotides from each 3’ end of viral 
cDNA, leaving conserved CA nucleotides at the 3’ ends. 
2. DNA strand transfer. The 3’ ends of the viral cDNA act as nucleophiles: 
they attack two phosphodiester bonds that are located on the opposite strands 
of the host DNA, break these bonds and join viral cDNA to the host DNA in 
one step (Engelman et al., 1991). The target sites are separated by 5 bp. As a 
result, an integration intermediate is formed, in which the 3’ ends of the viral 
cDNA are covalently linked to the host DNA and the 5’ ends are free.  
3. Reparation and completion. The 5’-overhangs of the viral cDNA are 
removed, the single-strand gaps between the viral and host DNA are filled 
(as a result, the provirus is flanked by 5 base-pair duplications), and the viral 
DNA is ligated with the host DNA. This step is probably performed by 
cellular enzymes.  
 
The integration of the viral genome into a chromosome leads to a successful 
replication. In some cases, the viral cDNA forms circles, which are dead-end 
products of the virus replication cycle (Farnet and Haseltine, 1991). 
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1.5.4 HIV-1 latency 
After integration, the provirus can undergo different fates. In most cases, the 
replication cycle proceeds and new virions are formed, but in approximately 5% 
of the cases the proviruses remain in a latent form. The mechanisms that control 
HIV latency are complex and incompletely understood. They include transcrip-
tional interference (the effect of neighboring cellular promoters), transcriptional 
activator and repressor influence (their activities and availabilities partially 
depend on the state of the host cell), chromatin structure and nucleosome modi-
fication, and some other factors. Latent provirus can be awakened and can serve 
as a source of new virions (Van Lint et al., 2013; Ruelas and Greene, 2013). 
HIV-1 latency represents the major obstacle in anti-HIV-1 therapy, as current 
antivirals cannot eliminate latent provirus, and there are no drugs that can acti-
vate (and subsequently eliminate) latent proviruses.  
 
 
1.5.5 Transcription and transport of viral mRNAs to the cytoplasm 
Viral mRNAs are synthesized, processed (spliced, capped, polyadenylated) and 
transported out of the nucleus by cellular mRNA synthesis/processing machin-
ery (for review, see (Karn and Stoltzfus, 2012; Leblanc et al., 2013; Stoltzfus, 
2009)). Viral mRNAs are produced by RNA polymerase II, which recognizes 
the viral promoter in the left LTR. Transcription begins at the 5’-end of the R 
region, and the poly(A) tail is added to the 3’-end of the R region in the right 
LTR. Due to alternative splicing, not only a full-length RNA transcript but also 
more than 40 different spliced viral mRNAs are produced (Ocwieja et al., 2012; 
Purcell and Martin, 1993). They can be divided into 3 groups:  
- a group of completely spliced 1.8 kb mRNAs (encoding the regulatory pro-
teins Tat, Rev, and Nef), 
- a group of incompletely spliced 4 kb mRNAs (encoding Env and the acces-
sory proteins Vif, Vpr, and Vpu), 
- single unspliced 9 kb mRNA (encoding the Gag and Gag-pol polyproteins 
and serving as genomic RNA for new virions).  
 
First, only completely spliced mRNAs are produced because only they can be 
transported out of the nucleus by cellular machinery. Their quantities are low 
due to the inefficiency of the elongation reaction. In the absence of Tat, RNA 
polymerase II pauses after it has synthesized the TAR element, a stem-loop 
structure present at the 5’ end of the viral RNA. The cellular negative elonga-
tion factors DSIF and NELF bind to the paused RNA polymerase II and TAR 
element and prevent further RNA synthesis. However, this block is not abso-
lute, and some amount of the mRNAs that encode the Tat and Rev proteins are 
still synthesized and exported to the cytoplasm. Once the Tat and Rev proteins 
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are produced, they enter the nucleus, where they help produce incompletely 
spliced and unspliced RNAs in large quantities. 
Tat increases the total amount of newly synthesized viral mRNA. Tat stim-
ulates elongation from the viral promoter by binding to TAR RNA and recruit-
ing P-TEFb to the complex (Mancebo et al., 1997; Tahirov et al., 2010; Zhu et 
al., 1997). P-TEFb is a kinase and a positive transcription elongation factor. 
Upon binding with Tat, it is activated; it then phosphorylates the C-terminal 
domain of RNA polymerase II, as well as NELF and DSIF. This leads to the 
dissociation of NELF from the complex, the conversion of DSIF from repressor 
to activator of transcription and the enhancement of RNA polymerase II proces-
sivity (Fujinaga et al., 2004; Ivanov et al., 2000; Kim et al., 2002; Yamada et 
al., 2006). 
Rev helps transport incompletely spliced and unspliced mRNAs out of the 
nuclei of infected cells. This is mediated by the binding of Rev to the Rev-
responsive element (RRE), a stem-loop structure that is present in the env gene 
of the viral mRNAs (Heaphy et al., 1990; Malim et al., 1989). When Rev binds 
to HIV-1 RNA, it interacts with the proteins that make up the nuclear pore 
complex (NPC) and thus both Rev and HIV-1 mRNAs are transported into the 
cytoplasm. After that, Rev is released from the viral RNA and re-enters the 
nucleus (Fischer et al., 1995; Henderson and Percipalle, 1997). 
 
 
1.5.6 Translation of HIV-1 mRNAs 
HIV-1 mRNAs are translated mainly similar to cellular mRNAs: one mRNA 
encodes for one protein and is translated by a cap-dependent mechanism (for 
review, see (Bolinger and Boris-Lawrie, 2009; de Breyne et al., 2013; Guerrero 
et al., 2015). Cap-dependent translation is initiated when translation initiation 
factors recognize the cap structure at the 5’ end of the mRNA. After that, the 
40S ribosomal subunit is engaged, and a 43S ribosomal complex is formed. 
This complex scans the mRNA until it finds an AUG initiation codon within a 
proper Kozak consensus sequence; this is followed by the assembly of the 80S 
ribosome and the start of translation. 
All transcripts of HIV-1 have the same 5’ leader region, which is rather long 
(~300 nt) and highly structured. This region contains important regulatory 
sequences, including TAR, PBS and several others, which may have specific 
RNA secondary structures that complicate ribosome scanning. Therefore, many 
cellular and viral factors are engaged to increase translation efficiency, includ-
ing the cellular RNA Helicase DDX3 (Soto-Rifo et al., 2012, 2013) and RNA 
Helicase A (RHA) (Fujii et al., 2001), the viral protein Rev (Groom et al., 2009) 
and others. 
 
 
In addition, some HIV-1 mRNAs use special mechanisms for translation: 
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- The mRNA encoding Vpu-env is both structurally and functionally 
bicistronic; it contains two open reading frames (encoding the Vpu and Env 
proteins), and both of them can be translated (Schwartz et al., 1990, 1992). 
The mechanism used is called leaky scanning: start codon for Vpu occurs 
first, but as it is surrounded by a weak Kozak sequence, the 43S ribosomal 
complex sometimes skips it and initiates translation from the Env start 
codon. 
- The unspliced mRNA (genomic RNA) encodes the Gag and Gag-Pol poly-
proteins. These two polyproteins are synthesized using a –1 ribosomal 
frameshift. Gag polyprotein, coding sequence of which is localized upstream 
of the frameshift signal, is approximately 20-fold more abundant. The –1 
ribosomal frameshift occurs at a frequency of ~5% and results in the 
synthesis of the Gag-Pol polyprotein (Jacks et al., 1988). The two main fac-
tors that are required for frameshifting to occur are located ~200 nt upstream 
of the Gag termination codon. They include the heptanucleotide slippery 
sequence (UUUUUUA) and the downstream stem-loop pseudoknot 
structure, which is called the frameshift stimulatory signal (FSS). The FSS 
forces the ribosome to pause and to then shift one nucleotide backwards on 
the slippery sequence. As a result, the mRNA reading frame is changed, and 
the gag termination codon is shifted out of frame (Dulude et al., 2002; 
Gaudin et al., 2005; Staple and Butcher, 2005). Leaky scanning and 
frameshift mechanisms help achieve the correct ratio of viral Gag and Pol 
proteins. 
 
Although (as was mentioned above) all viral mRNAs have the same leader 
sequence, only translation from the unspliced mRNA can be initiated via an 
additional IRES (internal ribosome entry site)-dependent mechanism. It has 
been shown that the genomic mRNA contains 2 IRES sites: one within the 5’ 
UTR (called HIV-1 IRES) (Brasey et al., 2003) and the other within the gag 
coding region (called HIV-1 Gag IRES) (Buck et al., 2001). IRES activity de-
pends on cellular and viral proteins, which can act as RNA chaperones and are 
required for its proper conformation. Cap-dependent initiation occurs under 
normal physiological conditions (Berkhout et al., 2011; Ricci et al., 2008), but 
the virus can switch to the IRES-dependent mechanism during stress (Gendron 
et al., 2011; Monette et al., 2009), virus-induced cell cycle arrest at the G2/M 
phase or under conditions of protein translation reduction (Brasey et al., 2003; 
Vallejos et al., 2011). 
 
 
1.5.7 Assembly, budding and maturation of HIV-1 virions 
To create a new infectious virion, all of the required components must meet and 
correctly assemble on the plasma membrane, after which the formed particle 
buds from the cell and matures (Kuzembayeva et al., 2014; Meng and Lever, 
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2013; Ono, 2010; Sundquist and Kräusslich, 2012). This is a complex process 
that is driven mostly by the Gag polyprotein. 
Two viral integral membrane proteins, Vpu and Env, are synthesized from 
the same bicistronic mRNA; translation occurs in the rough endoplasmic retic-
ulum, and the synthesized proteins are co-translationally inserted into the mem-
brane. They are transported to the plasma membrane via vesicular transport 
(Checkley et al., 2011; Strebel et al., 1989). 
Gag, Gag-Pol and other viral proteins are synthesized by cytosolic poly-
somes and are transported to the plasma membrane probably via Gag’s interac-
tions with cellular trafficking pathways (Camus et al., 2007; Dong et al., 2005; 
Martinez et al., 2008).  
Gag consists of several domains (staring from the N-terminus of the poly-
protein): the matrix, capsid and nucleocapsid proteins and finally the C-terminal 
p6 peptide. There are also two spacer peptides, p1 and p2, that flank the nucleo-
capsid domain. The matrix domain (MA) anchors Gag to the plasma membrane 
and probably recruits the Env protein to the site of particle formation (Checkley 
et al., 2011). The capsid domain (CA) is involved in different protein-protein 
interactions: it is partially responsible for Gag multimerization and the 
incorporation of some viral and host proteins into the particle. The nucleocapsid 
domain (NC) binds RNA and recruits a dimer of viral genomic mRNA. P6 is a 
protein-binding domain: it binds the accessory viral protein Vpr and attracts 
proteins from the cellular ESCRT (endosomal sorting complex required for 
transport) pathway that are required for particle budding. 
Viral genomic RNA is synthesized in the nucleus and is then transported to 
the cytoplasm. Genomic RNA forms dimers, which are recognized by Gag and 
transported to the plasma membrane, where they nucleate new particle assembly 
(Kutluay and Bieniasz, 2010). New particles bud from the cell with the help of 
the cellular ESCRT complex (Meng and Lever, 2013). After release of the parti-
cle it matures, the viral protease cleaves Gag into individual proteins; this pro-
cess leads to major structural changes in the formed virions. 
Virion release is not the only way in which HIV-1 spreads within an infected 
organism. Virus can also be efficiently transmitted via direct cell-to-cell con-
tacts through virological synapses; this process is similar to that described 
above (including the virion assembly, budding and maturation steps) 
(Bourinbaiar and Phillips, 1991; Haller and Fackler, 2008; Martin et al., 2010). 
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2. REVERSE TRANSCRIPTASE AND REVERSE  
TRANSCRIPTION OF HIV-1 
 
Reverse transcriptase (revertase, RNA-dependent DNA polymerase, RdDp) is a 
DNA polymerase, and its main function is DNA synthesis (Herschhorn and 
Hizi, 2010). Reverse transcriptase has a lot in common with other DNA 
polymerases (in structure, sequence of polymerase active site and mechanism of 
DNA synthesis), but unlike most other DNA polymerases, which can use only 
DNA as a template, reverse transcriptases can use either DNA or RNA as a 
template. Reverse transcriptases have been found in different types of viruses, 
prokaryotes and eukaryotes, but in this chapter I will describe only HIV-1 re-
verse transcriptase. 
 
 
2.1 History of discovery 
Reverse transcriptase and the process of reverse transcription were discovered 
in 1970 (Baltimore, 1970; Temin and Mizutani, 1970); this discovery had a 
great impact on science and medicine (Menéndez-Arias and Berkhout, 2008). 
First, it complemented the central dogma of molecular biology. Previously, it 
was thought that information could be transmitted only from DNA to RNA to 
protein (or from RNA to RNA to protein for some RNA viruses). The discovery 
of reverse transcription proved that information can be transmitted in the re-
verse order (from RNA to DNA; this is also how the enzyme obtained its name 
(Crick, 1970)). Reverse transcription was first discovered in oncogenic retrovi-
ruses (Rauscher mouse leukemia and Rous sarcoma viruses), which facilitated 
the understanding of some of the mechanisms that these viruses used to drive 
oncotransformation. Just before the discovery of HIV-1, reverse transcription 
was being extensively studied, and researchers were trying to find ways to 
inhibit reverse transcriptase to fight cancer (Gallo, 2002). These technologies 
and findings became very useful for anti-HIV-1 drug development. For exam-
ple, the first antiretroviral drug that was approved by FDA for clinical use in 
HIV-infected patients was the reverse transcriptase inhibitor azidothymidine 
(AZT or zidovudine) (Mitsuya et al., 1985), which was originally designed as 
an anti-cancer drug candidate. Reverse transcriptase inhibitors are still very 
important in ART: currently, they constitute roughly half of all anti-HIV-1 
drugs and are divided into two main classes according to the principles of their 
actions (see below for details).  
 
 
2.2 Biogenesis of HIV-1 reverse transcriptase 
HIV-1 reverse transcriptase is synthesized as a part of the Gag-Pol polyprotein 
and because it contains Gag it becomes packaged into budding particles. During 
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the maturation of HIV-1 virions, reverse transcriptase is cleaved from the 
polyprotein by the viral protease. Active HIV-1 reverse transcriptase is a 
heterodimer and consists of two subunits: p51 and p66. The smaller subunit is 
similar to the larger one except that it is truncated at the C-terminus (Lowe et 
al., 1988; di Marzo Veronese et al., 1986). It is known that initially the viral 
protease cleaves two full polypeptides from the precursor. Then, two subunits 
form a p66/p66 homodimer, enabling the final protease cleavage step that leads 
to p66/p51 heterodimer formation (Sluis-Cremer et al., 2004). 
 
 
2.3 Structure of HIV-1 reverse transcriptase 
Of the two subunits of HIV-1 reverse transcriptase, only the larger (p66) subunit 
is enzymatically active (Figure 3). This subunit consists of 560 amino acid (aa) 
residues and has two enzymatically active domains: the N-terminal DNA poly-
merase domain and the C-terminal RNase H domain. The smaller subunit (p51) 
is shorter; it contains a 440-aa-long DNA polymerase domain but lacks an 
RNase H domain (Kohlstaedt et al., 1992; di Marzo Veronese et al., 1986). 
The 3D-structure of the DNA polymerase domain of the p66 subunit is sim-
ilar to the Klenow fragment of Escherichia coli DNA polymerase I and has a 
“right-handed” structure (Figure 4). It has 4 subdomains: fingers, palm, thumb, 
and connection. These subdomains and the RNase H domain are arranged side-
by-side and therefore the p66 subunit has an elongated structure (Jacobo-Molina 
et al., 1991). The p66 subunit contains two active sites: a polymerase active site 
(responsible for DNA synthesis) and an RNaseH active site (responsible for the 
destruction of RNA contained in DNA:RNA heteroduplexes). Between the 
polymerase and RNaseH active sites, there is a binding cleft where a nucleic 
acid substrate lies (Jacobo-Molina et al., 1991). Reverse transcriptase mostly 
binds the sugar-phosphate backbones of DNA and RNA (Ding et al., 1998). The 
distance between the polymerase and RNase H active sites is approximately 60 
Å, which can fit a DNA-DNA duplex that is 17-nucleotides long or an RNA-
DNA duplex that is 18-nucleotides long. Near the polymerase active site, the 
DNA-DNA duplex structure is close to a B-form, while near the RNaseH active 
site its structure is close to an A form. To fit into the binding cleft, an 
RNA/DNA heteroduplex is bent by approximately 35º (Jacobo-Molina et al., 
1991; Nowotny et al., 2007; Sarafianos et al., 2001). 
The DNA polymerase domains of the p66 and p51 subunits have identical 
primary and secondary structures, with the same fingers, palm, thumb and con-
nection subdomains. However, the spatial arrangement of these subdomains in p51 
is drastically different from that in p66. As a consequence, the p51 subunit is more 
tightly packed and has a structural role; it also participates in tRNALys3 binding and 
affects the RNase H activity of p66 (Mishima and Steitz, 1995; Sevilya et al., 2001, 
2003). The fact that two polypeptides with identical sequences can adopt two very 
different conformations and perform different functions helps the virus get more out 
of its limited genome (Kohlstaedt et al., 1992).  
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The polymerase active site of p66 lies within the palm subdomain and con-
sists of three aspartic acid residues (Asp110, Asp185, and Asp186), which bind 
two divalent cations (Mg2+) that are required for catalysis (Ding et al., 1998). 
Asp185 and Asp186 are a part of the YXDD (Tyr(X)AspAsp) motif, which is 
highly conserved among many polymerases and may be a sign of their common 
origin (Argos, 1988; Kamer and Argos, 1984). The other part of this motif is 
represented by Tyr183 and Met184. These residues interact with nucleic acids 
and position the template-primer complex correctly in relation to the polymer-
ase active site (Ding et al., 1998). 
Next to the polymerase active site, there are several special sites where re-
verse transcriptase interacts with nucleic acid substrate:  
- The P site priming site, where 3’-OH group of the primer is situated (Huang 
et al., 1998; Jacobo-Molina et al., 1991). 
- The N site nucleotide binding site that binds dNTPs (Huang et al., 1998). It 
includes several important residues: 1. Tyr115 (binds to the deoxyribose ring 
and discriminates between rNTPs and dNTPs) (Boyer et al., 2000; Gao et al., 
1997; Martín-Hernández et al., 1996), 2. Arg72 and Lys65 (interact with the 
triphosphate group) and 3. Gln151 (binds to the 3’-OH group) (Huang et al., 
1998). 
- The template grip consists of residues from the palm and fingers and inter-
acts with the template strand.  
- The primer grip consists of residues from the palm and thumb and interacts 
with the primer strand. Template and primer grips help to correctly position 
primer and template ends relative to the active site (Jacobo-Molina et al., 
1991). 
 
 
 
 
Figure 3. Structure of HIV-1 reverse transcriptase (taken from PDB ID: 1IKW). 
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Figure 4. Ribbon representation of fingers, thumb and palm subdomains of HIV-1 
reverse transcriptase p66 subunit (taken from PDB ID: 1IKW). 
 
 
2.4 The process of reverse transcription  
Reverse transcriptase of HIV-1 (and other retroviruses) has two different activi-
ties: 1) it can synthesize DNA using RNA or DNA as a template (DNA poly-
merase activity), and 2) it can destroy RNA in RNA:DNA heteroduplexes 
(RNaseH activity).  
The main steps of HIV-1 reverse transcription are as follows (Götte et al., 
1999; Hu and Hughes, 2012): 
1. Initiation of minus-strand DNA synthesis (Figure 5A, 5B). As with any DNA 
polymerase, reverse transcriptase requires a DNA or RNA primer with a free 
3’-OH group for the initiation of synthesis. In the case of HIV-1, tRNALys3 
serves as a primer. Its 3’ end is annealed to the primer-binding site (PBS) of 
the viral RNA (Figure 5A). DNA synthesis starts from the 3’ end of 
tRNALys3 and proceeds until it reaches the 5’ end of the template strand. The 
addition of the first 6 nucleotides is slow, probably due to some structural 
features of the primer, but then the polymerization rate increases (Lanchy et 
al., 1996, 1998). RNA in the formed RNA:DNA heteroduplex is destroyed 
by the RNase H activity of reverse transcriptase, while tRNALys3 and the 
PBS region are left untouched (Figure 5B). The resulting short DNA 
fragment that is attached to tRNALys3 is called minus-strand strong-stop 
DNA. 
2. First strand transfer (Figure 5C). To continue minus-strand DNA synthesis, 
the minus-strand strong-stop DNA must be transferred to the 3’ end of the 
genomic RNA (either the same or the other copy of genomic RNA) (van 
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Wamel and Berkhout, 1998). This is possible because each of the HIV-1 
RNA molecules have two identical R regions at their 5’ and 3’ ends (Figure 
2A). After the R region at the 5’ end is copied and the template RNA of the 
copied region is destroyed, the minus-strand DNA fragment can comple-
mentarily bind the R region at the 3’ end of the genomic RNA. Then, syn-
thesis of the minus-strand DNA can proceed until the PBS region of the 
RNA template is reached. It is worth noting that PBS is the end of the tem-
plate because the rest of the template was destroyed by RNase H. 
3. Initiation of plus-strand synthesis (Figure 5D, 5E, 5F). During minus-strand 
synthesis, a heteroduplex of template RNA and new DNA is formed. The 
RNaseH activity of reverse transcriptase destroys the RNA in this heterodu-
plex, but not completely: some RNA regions, called PPTs (polypurine 
tracts), are resistant to RNaseH degradation (Figure 5D). HIV-1 has 2 PPTs: 
a 3’ PPT and a central one. They both serve as primers for the initiation of 
plus-strand DNA synthesis (using nascent minus-strand DNA as a template) 
(Figure 5E). Plus-strand DNA synthesis continues with the copying of the 
PBS region of tRNALys3 and pauses when it reaches a modified A base in the 
tRNA primer. At that point, reverse transcriptase cuts the tRNA off of the 
minus-strand DNA (leaving a single tRNA base attached to the 5’ end of the 
minus-strand DNA) and therefore plus-strand strong-stop DNA is formed 
(Figure 5F). 
4. Second-strand transfer (Figure 5G). Plus-strand strong-stop DNA has a 3’ 
overhang (created as a result of the cutting off of the tRNALys3 primer), 
which is complementary to the PBS at the 3’ region of the minus-strand 
DNA. These regions interact with each other; usually, this is an intramolec-
ular process, and a circular structure is formed (Yu et al., 1998). Note that 
Figures 5F and 5G are identical; the structure depicted in Figure 5G is a cir-
cular form of 5F. 
5. Synthesis of plus- and minus-strands proceeds (Figure 5H and 5I). Nascent 
DNA strands are used as templates for each other. Subsequent DNA synthe-
sis requires the strand displacement activity of reverse transcriptase. Syn-
thesis is complete when reverse transcriptase reaches the end of the template. 
The resulting cDNA is longer than the genomic RNA (it has identical left 
and right LTRs) and has plus-strand overlap in its center. 
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Figure 5. A schematic of the HIV-1 reverse transcription process (explanation in the 
text). 
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2.5 Molecular mechanisms used by reverse transcriptase  
and its polymerization reaction cycle 
There are several steps in the polymerization reaction that are coupled with 
certain conformational changes in reverse transcriptase (these have been called 
“retroviral gymnastics” (Abbondanzieri and Le Grice, 2014; Abbondanzieri et 
al., 2008). 
1. Unligated reverse transcriptase before the reaction has a “closed” confor-
mation (the thumb subdomain touches the fingers subdomain). 
2. In the first step, reverse transcriptase binds a template-primer duplex so that 
the 3’-OH group of the primer is located at the priming site (P site), which is 
located near the polymerase active site (Jacobo-Molina et al., 1991) (Huang 
et al., 1998). This binding is accompanied by the moving of the thumb 
subdomain to approximately 30º away from the fingers, enabling the enzyme 
to adopt an “open” conformation (Hsiou et al., 1996; Rodgers et al., 1995).  
3. The next step is dNTP binding to the nucleotide-binding site (N site). This 
binding results in the formation of a ternary complex (Huang et al., 1998). 
4. Then, part of the fingers subdomain moves to the thumb subdomain, forming 
an activated closed ternary complex. Thus, the fingers subdomain closes 
around the incoming dNTP, which helps to correctly align the α-phosphate 
of the dNTP and the 3’-OH of the primer relative to the polymerase active 
site. This is the rate-limiting step in single nucleotide incorporation 
reactions. 
5. The 3’-OH of the primer attacks the α-phosphate of the incoming dNTP, and 
this leads to the formation of a 3’-5’ phosphodiester bond and the release of 
pyrophosphate (PPi). Reverse transcriptase facilitates this reaction via a 
“two-metal-ion” mechanism (Steitz, 1998). Two magnesium ions coordinate 
the oxygen atoms of all three phosphates of the incoming dNTP and three 
catalytic aspartic-acid residues: one Mg2+ decreases the affinity of the 3’-OH 
of the primer for hydrogen and thus promotes 3’ O- attack on the  
α-phosphate; the other Mg2+ facilitates pyrophosphate release. Together, 
these two Mg2+ ions stabilize the charge and the structure of the transition 
state. After the formation of a 3’-5’ phosphodiester bond, the fingers domain 
opens and allows PPi to leave the enzyme.  
6. To bind the next incoming dNTP, a nucleic acid substrate must translocate 
relative to the reverse transcriptase so that the newly incorporated nucleotide 
moves from the N site to the P site. 
 
 
In the case of efficient translocation, reverse transcriptase continues polymeri-
zation; this is called processive synthesis. However, the enzyme can also fall off 
of the nucleic acid substrate; in this case, polymerization starts again from the 
beginning (when the enzyme is in the “closed” conformation).  
Overall, reverse transcriptase is a comparatively slow polymerase: its 
polymerization rate is 1–15 nucleotides per second, and it takes about 4 hours to 
31 
 
synthesize a full viral cDNA (Kim et al., 2010, 1989). It has been shown that 
reverse transcriptase can add a few hundred nucleotides in a single round of 
processive synthesis. However, it falls off of the substrate rather often, espe-
cially when it encounters difficult RNA secondary structures (pseudo-knots and 
so on) (Avidan et al., 2002). Thus, the processivity of reverse transcriptase (how 
many nucleotides are added before the enzyme falls off of the substrate) is quite 
low. Accordingly, the dissociation rate of the enzyme from the substrate limits 
the overall reaction rate (Avidan et al., 2002; Kati et al., 1992; Rittinger et al., 
1995).  
The fidelity of DNA synthesis (how accurately the template is copied) is also 
quite low, as reverse transcriptase lacks any proofreading activity: its mutation 
rate is 10–4 – 10–5 mutations per nucleotide (Menéndez-Arias, 2009; Preston et 
al., 1988; Roberts et al., 1988). 
 
In addition to polymerase and RNaseH activity, HIV-1 reverse transcriptase 
also has strand transfer and strand displacement activities. Strand transfer activ-
ity is involved in both strand transfer events (the first being minus-strand DNA 
transfer and the second being plus-strand DNA transfer) (Basu et al., 2008). 
Strand displacement activity is necessary for plus-strand DNA synthesis; while 
copying minus-strand DNA, the remains of genomic RNA (RNaseH activity of 
reverse transcriptase cannot eliminate RNA completely) must be removed. 
 
 
2.6 RNase H activity of HIV-1 reverse transcriptase 
2.6.1 Structure 
The structure of the RNase H domain of the p66 subunit is very similar to the 
RNase H enzymes of Escherichia coli and Thermus thermophilus (Davies et al., 
1991; Schultz and Champoux, 2008). The active site of the enzyme consists of 4 
highly conserved residues: Asp443, Glu478, Asp498, and Asp549. They coor-
dinate two Mg2+ ions, which are important for RNase H activity (Nowotny et 
al., 2005).  
RNase H primer grip is a region located close to the RNaseH active site, 
which consists of residues from the p66 and p51 subunits. It binds nucleic acid 
substrate and helps to position it correctly at both the RNase H and DNA poly-
merase active sites, and it also controls the cleavage specificity of RNase H 
(Sarafianos et al., 2001). 
 
2.6.2 Enzyme activity 
RNase H is an endonuclease that cleaves the RNA in RNA-DNA heterodu-
plexes: it hydrolyses the phosphodiester bond between two ribonucleotide resi-
dues and produces 3’-OH and 5’-phosphate ends (DeStefano et al., 1991; Krug 
and Berger, 1989). RNase H catalyzes this cleavage via a two-metal ion mecha-
nism. As was mentioned above, there are two Mg2+ ions in the RNase H active 
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site. The first activates a nucleophilic water molecule, and the second (or both 
of them) stabilizes the transition state intermediate (Nowotny and Yang, 2006; 
Nowotny et al., 2005, 2007). 
 
 
 
Figure 6. Modes of HIV-1 RNase H cleavage (from (Schultz and Champoux, 2008) 
with modifications). Reverse transcriptase is shown in blue-grey (pol: polymerase active 
site, RNase H: RNase H active site); DNA is shown in green; RNA is shown in red. The 
3’ ends of nucleic acids are indicated by arrowheads.  
 
 
2.6.3 Modes of RNase H cleavage 
1. DNA 3’-end-directed cleavage (can happen simultaneously with or inde-
pendently from polymerization) (Figure 6A). The binding of reverse tran-
scriptase to a nucleic acid substrate is identical to its binding during DNA 
synthesis. The polymerase domain is connected to the 3’-end of the nascent 
DNA chain, and the RNase H domain is located 15–20 nucleotides behind 
(towards the 5’-end of the nascent DNA chain) the polymerase active site. 
DNA 3’-end-directed cleavage leads to nicks and gaps in the RNA template.  
2. RNA 5’-end-directed cleavage (polymerization-independent) (Figure 6B). 
Reverse transcriptase binds to an RNA-DNA heteroduplex in which the 
RNA template is nicked. The polymerase domain is connected to the 5’ end 
of the nicked RNA, and the RNase H domain is 13–19 nucleotides ahead of 
it (towards the 3’-end of the RNA template strand). 
3. Internal cleavage (polymerization-independent) (Figure 6C). Reverse tran-
scriptase binds to an RNA-DNA heteroduplex irrespective of its nucleic acid 
ends. 
 
Cleavage by the RNase H domain of HIV-1 reverse transcriptase is not se-
quence-specific. However, this reaction must produce PPT primers and the 5’ 
end of the negative DNA strand very precisely.  
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2.7 Other proteins involved in the process of  
HIV-1 reverse transcription 
In principle, HIV-1 reverse transcriptase is absolutely sufficient for viral cDNA 
synthesis. However, there are a number of viral and cellular proteins that take 
part (either directly or indirectly) in this process. 
 
 
2.7.1 Viral proteins involved in reverse transcription 
2.7.1.1 Nucleocapsid protein 
Nucleocapsid protein binds nucleic acids mostly in non-specific manner. NC 
acts as a nucleic acid chaperone: it destabilizes secondary structures and pro-
motes the formation of more stable nucleic acid duplexes (Levin et al., 2010). 
At the beginning of DNA synthesis, it helps to anneal the tRNALys3 primer to 
the PBS site and facilitates the copying of a highly structured 5’ region of HIV-
1 RNA (Li et al., 1996; Sleiman et al., 2012). Nucleocapsid is important in 
strand-transfer reactions (especially in the first minus-strand transfer, when it 
unwinds the R region) (Rodríguez-Rodríguez et al., 1995). It also helps to re-
move the already-copied and fragmented (due to the activity of RNase H) 
pieces of RNA template from RNA-DNA heteroduplexes, thus ensuring that the 
initiation of positive-strand synthesis mostly occurs from PPT fragments (Jacob 
and DeStefano, 2008; Post et al., 2009). 
 
 
2.7.1.2 Integrase 
Integrase physically interacts with reverse transcriptase and promotes the early 
steps of DNA synthesis. It increases the processivity of reverse transcriptase 
probably by stabilizing it and enhancing its interactions with genomic RNA 
(Dobard et al., 2007; Wu et al., 1999; Zhu et al., 2004). 
 
 
2.7.1.3 Viral protein R (Vpr) 
Vpr is an accessory protein (not required for viral replication in some cell 
types), but it is abundant in the HIV-1 virion core, RTC and PIC. Like many 
viral proteins, it is a multifunctional protein, and it probably also influences 
reverse transcription. For example, it was shown that several peptides derived 
from Vpr could bind to reverse transcriptase and inhibit its activity (Gleenberg 
et al., 2007). Also, Vpr interacts with tRNALys3-synthetase and probably inhibits 
the acetylation of tRNALys3, thus facilitating the initiation of DNA synthesis 
(tRNALys3 serves as a primer for viral DNA synthesis, and its 3’-terminus must 
not be bound to the amino acid) (Stark and Hay, 1998). 
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2.7.1.4 Negative factor (Nef), Trans-Activator  
of transcription (Tat) and matrix protein 
Nef and Tat are accessory proteins. They increase the effectiveness of viral 
DNA synthesis, but the mechanisms of their actions are not completely under-
stood; probably, their effects on reverse transcription are indirect (about nef: 
(Aiken and Trono, 1995; Schwartz et al., 1995), (about tat: (Harrich et al., 
1997)). Matrix protein also influences some early stages of viral replication, 
although whether it affects reverse transcription has not been shown (Kiernan et 
al., 1998). 
 
 
2.7.2 Cellular proteins involved in HIV-1 reverse transcription 
2.7.2.1 Topoisomerase I 
Topoisomerase I is an enzyme that helps resolve overwound DNA structures: it 
cuts a single DNA strand, allows DNA to unwind and then joins the phosphate 
backbone again. It physically interacts with HIV-1 NC and is a part of the virion 
core (Jardine et al., 1993). It stimulates the process of reverse transcription, but 
the exact mechanism of this stimulation is not clear (Shoya et al., 2003; 
Takahashi et al., 1995). 
 
 
2.7.2.2 Proteins from the APOBEC group, uracil DNA glycosylase  
(UNG2) and the role of viral protein Vif (viral infectivity factor) 
APOBEC (apolipoprotein B mRNA-editing enzyme catalytic polypeptide) is a 
family of RNA/DNA editing enzymes that deaminate cytidine into uridine resi-
dues. In the absence of Vif, APOBEC3 proteins inhibit HIV-1 replication 
(Moris et al., 2014; Sheehy et al., 2002) because they are packaged into assem-
bling virions. This packaging occurs due to the interaction that occurs between 
APOBEC3, viral RNA and the NC part of the Gag polyprotein. During reverse 
transcription, APOBEC3 proteins recognize single-stranded DNA and change C 
to U; this editing eventually leads to hypermutation in the complementary DNA 
strand (a large number of G residues are changed to adenosine residues) (Goila-
Gaur and Strebel, 2008). In some reports, it was found that hypermutation is not 
the only mechanism by which APOBEC proteins inhibit reverse transcription, 
but the alternative mechanism(s) of inhibition is not fully understood (Bishop et 
al., 2006; Holmes et al., 2007). 
Vif, an accessory protein of HIV-1, inhibits APOBEC3G/F activity. Briefly, 
Vif interacts with APOBEC3 proteins, targets them for proteasomal degradation 
and thus reduces their packaging into HIV-1 virions (Feng et al., 2014). Another 
way the virus evades damage caused by dUTP incorporation into DNA is 
through its use of the cellular enzyme uracil DNA glycosylase (UNG2). UNG2 
is packaged into assembling virions, and during reverse transcription it repairs 
incorrect G:U pairs with correct G:C pairs (Priet et al., 2003). 
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3. HIV-1 REVERSE TRANSCRIPTASE INHIBITORS 
3.1 Nucleoside (nucleotide) reverse  
transcriptase inhibitors (NRTI) 
3.1.1 General information 
Nucleoside reverse transcriptase inhibitors (NRTIs) were the first compounds 
found to suppress HIV-1 replication. Correspondingly, a representative of this 
class of compounds, 3’-azidothymidine (AZT, zidovudine), was the first com-
pound approved for clinical treatment of HIV-1-infected patients (Broder, 2010; 
Mitsuya et al., 1985). Currently, there are eight FDA-approved compounds 
from this class (see Table 1) (http://aidsinfo.nih.gov/drugs/search/ 
searchterm/2/1). All NRTIs are nucleoside analogs; the common property of 
these compounds is that they lack 3’-hydroxyl groups. All of these compounds 
are prodrugs; after entering the cell, they are phosphorylated by cellular 
enzymes into their active triphosphate forms. They compete with normal 
nucleotides for binding with reverse transcriptase and can be incorporated into 
nascent viral cDNA. Due to the lack of the 3’-hydroxyl, a phosphodiester bond 
with the next incoming dNTP cannot be formed, and as a result a cDNA chain 
with NRTI at its 3’ end cannot be elongated further (Cihlar and Ray, 2010; 
Menéndez-Arias, 2008; Sarafianos et al., 2009). NRTIs are, however, relatively 
toxic because in addition to HIV-1 reverse transcriptase they also inhibit 
cellular DNA polymerases, most prominently mitochondrial DNA-polymerase γ 
(Koczor and Lewis, 2010). As all modified nucleosides, NTRI-drugs are also 
potential mutagenic agents. 
 
 
3.1.2 Life and fate of NRTI inside an infected cell 
Cell entry. NRTIs are hydrophilic compounds and require carriers to cross the 
cellular membrane. For example, some nucleoside transporters influx NRTIs into 
the cell (Cass et al., 1999). In the opposite flow, other transporters, such as multi-
drug resistance related proteins (MRP4, MRP5 and MRP8), efflux NRTIs out of 
the cell, thus reducing their activity (Guo et al., 2003; Schuetz et al., 1999). 
Phosphorylation. NRTIs are converted into their active triphosphate forms 
by cellular enzymes. The efficiency of phosphorylation and the stability of 
NRTI-TP (triphosphates) inside of a cell influence NRTI activity. Phosphoryla-
tion is catalyzed by enzymes that usually phosphorylate normal nucleosides 
(Furman et al., 1986; Ho and Hitchcock, 1989; Van Rompay et al., 2000; 
Shewach et al., 1993); (addition of the second phosphate: (Bourdais et al., 
1996)) (addition of the third phosphate: (Krishnan et al., 2002)). For most 
NRTIs, the rate-limiting step is the addition of the first phosphate (Perno et al., 
1988). To overcome this problem, nucleotide inhibitors can be used. Thus, 
tenofovir already has the first phosphate and hence requires only the addition of 
the last two. For AZT, however, the rate-limiting step is the addition of the 
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second and third phosphates (Furman et al., 1986). AZT and d4T are 
phosphorylated by TK1, an S-phase specific enzyme, which is why they are not 
very active in resting cells (Gao et al., 1993).  
 
 
Table 1. Structures of NRTIs approved by the FDA (structures taken from (Menéndez-
Arias, 2008) 
Name(s)  
(year of approval) 
Structure Modifications present 
In sugar moiety In nitrogenous base 
Azidothymidine 
(AZT, zidovu-
dine) (1987) 
3’-hydroxyl group is 
replaced by  
3’-azidofunctional 
group 
thymidine analog; 
contains unmodified 
thymine base 
Didanosine (ddI) 
(1991) 
3’-hydroxyl group is 
absent 
guanosine analog; 
contains hypoxan-
thine as a base  
Zalcitabine (ddC, 
dideoxycytidine) 
(rarely used) 
(1992) 
3’-hydroxyl group is 
absent 
cytidine analog; 
contains unmodified 
cytosine base 
Stavudine (d4T) 
(1994) 
3’-hydroxyl group is 
absent; sugar ring is 
unsaturated 
thymidine analog; 
contains unmodified 
thymine base 
Lamivudine (3TC) 
(1995) 
 
3’-hydroxyl group is 
absent; C3’ is 
replaced with a 
sulfur; sugar is  
L-deoxyribose 
cytidine analog; 
contains unmodified 
cytosine base 
Abacavir (ABC) 
(1998) 
 
3’-hydroxyl group is 
absent; sugar ring is 
unsaturated; O4’ is 
replaced with a 
carbon 
guanosine analog; 
contains 6-modified 
diaminopurine ring 
Tenofovir diso-
proxil fumarate 
(TDF, tenofovir) 
(2001) prodrug of 
tenofovir (TFV) 
 
has an acyclic linker 
instead of a sugar 
moiety 
 
adenosine mono-
phosphate analog; 
contains unmodified 
adenine base 
Emtricitabine 
(FTC) (2003) 
 
3’-hydroxyl group  
is absent; C3’ is 
replaced with a 
sulfur; sugar is  
L-deoxyribose 
cytidine analog; 
fluorine at the  
5’-position  
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Inhibition of reverse transcription. NRTI-TPs compete with natural dNTPs for 
binding to HIV-1 reverse transcriptase. They occupy the nucleotide-binding site 
and become incorporated into the nascent cDNA chain instead of their natural 
prototypes (Huang et al., 1998; Ray et al., 2002). Their efficiency of incorpo-
ration depends upon the NRTI’s capability to mimic the interactions of the 
natural substrate with the enzyme. For example, reverse transcriptase incor-
porates thymidine analogs (AZT-TP and d4T-TP) as efficiently as their normal 
counterparts (Kerr and Anderson, 1997; Vaccaro et al., 2000). On the contrary, 
the incorporation of cytidine analogs (ddCTP and 3TC-TP) is less efficient 
(Feng and Anderson, 1999; Krebs et al., 1997). After reverse transcriptase 
incorporates NRTI into a DNA chain, the end of this chain is translocated to the 
priming site. Next, dNTP can bind reverse transcriptase at the nucleotide-bind-
ing site, but it cannot be incorporated into the DNA chain because NRTI lacks a 
3’-hydroxyl group and therefore cannot form a phosphodiester bond. 
 
 
3.1.3 Resistance 
There are two main mechanisms of resistance to NRTI: mutations that confer 
discrimination and those that confer excision; one reverse transcriptase can 
combine mutations of both types (Menéndez-Arias, 2008). Mutations that con-
fer reverse transcriptase resistance to NRTI can also decrease its fidelity (when 
compared to wild type enzyme in the absence of inhibitor) (Menéndez-Arias et 
al., 2003). I will give a general overview of both mechanisms. 
Discrimination mechanism. In this case, reverse transcriptase can “learn” to 
discriminate between normal dNTPs and their analogs without 3’-hydroxyl 
groups and does not incorporate the latter into the nascent cDNA chain. Muta-
tions in the nucleotide-binding site confer this type of resistance. There are 
several examples of such mutations, which can be found either individually or 
as double-mutations: 
1. M184V/I is associated with resistance to 3TС, FTC, ddC, ddI, and abacavir. 
Met 184 interacts with incoming dNTP at the 3’ prime end. The substitution of 
Met with amino acid residues having branched side chains (Val, Ile) creates 
steric hindrance in the dNTP binding site and decreases the rate of inhibitor 
binding and incorporation by reverse transcriptase (Gao et al., 2000; Huang et 
al., 1998; Sarafianos et al., 1999). When combined with the K65R mutation, it 
makes reverse transcriptase susceptible to TFV (Feng et al., 2006). 
2. The L74V (resistance to ddI, abacavir) and Q151M complex (resistance to 
AZT, ddI, ddC,d4T, abacavir and tenofovir) are mutations that change the 
hydrogen bonding network between reverse transcriptase and dNTP and 
make the presence of a 3’-OH in dNTP very important for binding to the 
enzyme, hence preventing the binding of NRTI-TPs (Deval et al., 2004a, 
2004b; Sarafianos et al., 2004). 
3. K65R is associated with resistance to TFV, ddC, d4T, 3TC, and ddI. Lys 65 
directly interacts with the triphosphate group of the incoming dNTP (Gu et 
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al., 1995; Huang et al., 1998; White et al., 2006). This mutation, however, 
makes the reverse transcriptase very susceptible to AZT (Parikh et al., 2007; 
White et al., 2005). 
 
Excision mechanism. In this case, NRTI can be incorporated into the cDNA 
chain, but it is then selectively removed by reverse transcriptase (Arion et al., 
1998; Boyer et al., 2001; Meyer et al., 1998, 1999). As one could expect, muta-
tions of amino acid residues that are located away from the nucleotide-binding 
site are involved in this type of resistance. There is also some selectivity, as this 
type of resistance occurs mainly against thymidine-analogs and therefore these 
mutations are called TAMs, or thymidine-analog mutations (resistance to AZT 
and d4T) (Hooker et al., 1996; Kellam et al., 1992; Larder and Kemp, 1989). 
Reverse transcriptase does not have the exonuclease activity that is required for 
true proofreading; instead, the excision reaction resembles the reaction of 
polymerization but run in reverse (Arion et al., 1998; Meyer et al., 1998, 1999). 
One of the mechanisms of excision is the following. First, NRTI is incorporated 
into the DNA chain. Then, elongated nascent DNA translocates and thus NRTI 
enters the priming site. Next, incoming dNTP binds the nucleotide-binding site 
of the enzyme, and the fingers close down, but the polymerization reaction does 
not occur, and the enzyme is stuck in the closed position. However, if the inhib-
itor is AZT, which has a long azido group, the binding rate of the next incoming 
dNTP is reduced, and the closed reverse transcriptase structure is destabilized. 
This allows the enzyme to translocate DNA in the reverse direction (thus, NRTI 
is again in the nucleotide binding site). Subsequently, reverse transcriptase 
excises NRTI using ATP as a donor of pyrophosphate (Boyer et al., 2001; 
Sarafianos et al., 2002). 
There are also a number of mutations that can make reverse transcriptase 
multi-drug resistant; for example, insertions of two amino acids in the fingers 
subdomain between residues 69 and 70, as well as some others. These muta-
tions probably destabilize reverse transcriptase complexes regardless of the type 
of NRTI that is bound to the enzyme (Boyer et al., 2002; Meyer et al., 2003). 
 
 
3.2 Non-nucleoside reverse  
transcriptase inhibitors (NNRTIs) 
3.2.1 General information 
NNRTIs are allosteric inhibitors of HIV-1 reverse transcriptase. They have very 
different chemical structures (Figure 7), but they all share the same mode of 
action: they bind non-covalently to a special site in the palm domain of the p66 
subunit of reverse transcriptase. This binding leads to conformational changes 
in the enzyme and to an inhibition of its polymerase activity. NNRTIs are not 
prodrugs; they do not require cellular metabolism to become active, as they are 
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already present in their active form (de Béthune, 2010; Sluis-Cremer and 
Tachedjian, 2008). 
 
 
 
Figure 7. Structures of FDA-approved NNRTIs 
 
 
Currently, 5 NNRTIs are approved by the FDA for clinical use: nevirapine 
(1996), delavirdine (1997), efavirenz (1998), etravirine (2008), and rilpivirine 
(2011) (http://aidsinfo.nih.gov/drugs/search/searchterm/3/1). The former three 
are first generation NNRTIs, while the latter two are second generation 
NNRTIs. NNRTIs are highly specific to HIV-1 reverse transcriptase and are 
unable to bind to and inhibit other retroviral reverse transcriptases (even that of 
HIV-2) or cellular enzymes. As such, they have comparatively low toxicity and 
very high therapeutic indexes; nevertheless, some side effects are still present 
(Balzarini, 2004). 
 
 
3.2.2 Chemical structure 
The NNRTIs are a group of small (<600 Da) compounds with diverse chemical 
structures and include more than 50 families of molecules (Balzarini, 2004; 
Zhan et al., 2013). In spite of their chemical diversity, NNRTIs contain com-
mon fragments, which participate in specific types of attractive noncovalent 
interactions. These fragments include the following: 
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1. Hydrocarbon-rich domain (involved in hydrophobic interactions, a type of 
interaction that occurs between nonpolar molecules). 
2. Aromatic ring (involved in π-π stacking, a type of hydrophobic interaction 
that occurs between aromatic rings when they are arranged like a stack of 
coins) 
3. Amide or thioamide moieties (involved in hydrogen bonding, a type of 
electrostatic interaction that occurs between an electronegative atom and a 
hydrogen atom (H) that is bound covalently to another electronegative atom 
(these electronegative atoms can be nitrogen (N), oxygen (O) or fluorine (F)) 
 
When NNTIs bind with reverse transcriptase, they can adopt two types of 
conformations:  
- The “Butterfly-like” conformation is common to the first generation 
NNRTIs. These compounds have two hydrophobic residues (wings) con-
nected by a linker group (body). Wing I lies next to the polymerase active 
site, and wing II is distal; the body lies at an angle of 110°–115° relative to 
the wings (Ding et al., 1995). Their structures are rigid, and they bind to re-
verse transcriptase in only one possible conformation; as such, only a single 
mutation in the NNRTI binding pocket is needed to make the virus resistant 
to the whole group of such inhibitors (Das et al., 2004). 
- The “Horseshoe-like” or “U-like” conformation is common to the second 
generation NNRTIs. Unlike inhibitors with “butterfly-like” structures, these 
compounds are more flexible and can bind to reverse transcriptase in several 
possible conformations, thus inhibiting viruses with a mutation(s) in the 
NNRTI binding pocket (Das et al., 2004). 
 
 
3.2.3 The NNRTI binding pocket 
The NNRTI binding pocket is a special site to which all NNRTIs bind (Figure 
5). It is located in the palm domain about 10 Å away from the polymerase ac-
tive site (Ren et al., 1995; Smerdon et al., 1994). It is absent in the normal 3D-
structure of reverse transcriptase and appears only when the enzyme and 
NNRTI interact (Kohlstaedt et al., 1992; Tantillo et al., 1994). The NNRTI 
binding pocket is flexible, and its conformation depends on the size and chemi-
cal nature of the NNRTI. It contains the hydrophobic sub-pocket (which is in-
volved in hydrophobic interactions with NNRTIs and includes the aromatic 
residues Tyr181, Tyr188, Phe227, and Trp229) and hydrophilic amino acid 
residues (for example, Lys101 or Lys103), which can form hydrogen bonds 
with select NNRTIs. Interestingly, the reverse transcriptases of HIV-1 and HIV-
2 have different amino acid residues at their 181 and 188 positions (HIV-1 has 
Tyr181 and Tyr188; HIV-2 has Ile181 and Leu188). This can partially explain 
why NNRTIs are not active against HIV-2 reverse transcriptase (Condra et al., 
1992). In addition, the NNRTI binding pocket contains additional residues that 
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are contributed by the p66 subunit and even some residues from the p51 
subunit. 
 
 
3.2.4 Mechanism of inhibition 
NNRTIs act as non-competitive inhibitors. They bind and inhibit the enzyme 
regardless of whether it is bound to a substrate or not (Debyser et al., 1992; 
Spence et al., 1995). The binding of an NNRTI to reverse transcriptase has 
several consequences: 
1. Conformational changes in the polymerase active site, especially in the 
YMDD motif (Asp185 and Asp186 residues change in their positions) 
(Esnouf et al., 1995). This inhibits phosphodiester bond formation, while 
the rate of dNTP binding to the reverse transcriptase is increased (Rittinger 
et al., 1995; Spence et al., 1995; Xia et al., 2007). 
2. Conformational changes in the “primer grip” (it moves about 5 Å upward), 
which makes it difficult to align the 3’ end of the primer relative to an in-
coming dNTP (Hsiou et al., 1996; Xia et al., 2007). 
3. Decreased mobility of the thumb subdomain (the “arthritic thumb” model), 
which inhibits the translocation of the primer-template duplex (Kohlstaedt 
et al., 1992; Tantillo et al., 1994). A slightly different hypothesis was pro-
posed by Temiz and Bahar (Temiz and Bahar, 2002). For nevirapine, it was 
shown that the amplitude of the subdomain movements does not change but 
rather that they change in direction. For the second generation NNRTI 
efavirenz, it was shown that the amplitude decreases in addition to changes 
in the orientations of the subdomain movements. 
 
 
3.2.5 Influence of NNRTI binding to particular  
steps of the reverse transcription reaction 
Minus-strand DNA synthesis. The inhibitory effect of NNRTI depends on the 
type of primer/template (DNA/DNA or RNA/DNA and their sequences) and 
increases with the length of DNA product. For example, a large amount of nevi-
rapine is required to inhibit minus-strong stop DNA synthesis, but further syn-
thesis of minus-strand DNA is readily inhibited with lower nevirapine concen-
trations (Quan et al., 1998). 
RNase H activity. The distance between the NNRTI-binding pocket and the 
RNase H active site is quite large, at approximately 60 Å. Nevertheless, 
NNRTIs influence the RNase H activity of reverse transcriptase according to 
the mode of RNase H cleavage; they can inhibit polymerase-independent or 
stimulate polymerase-dependent RNase H activity (Hang et al., 2007; Radzio 
and Sluis-Cremer, 2008; Shaw-Reid et al., 2005). 
Initiation of plus-strand DNA synthesis. This process is also very efficiently 
inhibited by NNRTIs (Grobler et al., 2007). NNRTIs suppress binding of dNTP 
to the enzyme-primer/template complex if the primer/template is PPT RNA 
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primer/DNA template. In addition, NNRTIs disfavor reverse transcriptase 
binding to the PPT RNA primer/DNA template complex in a polymerase-
dependent mode. 
 
 
3.2.6 Inhibition of other stages of the viral life cycle by NNRTIs 
Viral entry. The pyrimidinedione IQP-0410 acts as an NNRTI and also inhibits 
viral entry into the cell, as it also acts during the stage in which viral glycopro-
teins are already complexed with cellular receptors, but fusion with cellular 
membrane has not yet occurred (Buckheit et al., 2001). 
Gag-pol processing and new viral particle formation. Efavirenz is also a 
potent enhancer of reverse transcriptase dimerization (Tachedjian et al., 2001) 
and is therefore able to enhance gag-pol dimerization in the cell before particle 
formation. Protease (as well as reverse transcriptase) is synthesized as a part of 
the gag-pol polyprotein and is active in a dimer form. For this reason, the en-
hanced gag-pol dimerization that occurs in producer cells induces premature 
protease activity. Activated protease cleaves gag-pol before particle budding, 
thus leading to impaired particle formation (Figueiredo et al., 2006; Tachedjian 
et al., 2005). 
 
 
3.2.7 Resistance 
The emergence of resistant variants of HIV-1 is the main obstacle to the suc-
cessful application of NNRTIs in the clinic. This is especially the case for the 
first generation NNRTIs, as only a single mutation is needed to make the virus 
resistant to the whole class of compounds, whereas the second generation 
NNRTIs are active against these mutants. NNRTI resistant mutations mainly 
arise in the area adjacent to the NNRTI binding site (Ren and Stammers, 2008; 
Wensing et al., 2014). Here, I will provide a few examples of such resistance-
associated mutations. 
Mutations of Tyr181/Tyr188. Tyr181 can be mutated to Cys, and Tyr188 can 
be mutated to Cys/Ile/His. The Tyr181Cys mutation is very common in the 
clinic (Cheung et al., 2004). Tyrosines at positions 181 and 188 are involved in 
very important ring-stacking interactions with the first generation NNRTIs. 
Mutations of these residues to aliphatic amino acids without aromatic rings 
leads to the loss of such ring stacking interactions and decreases the abilities of 
NNRTIs to bind reverse transcriptase (Das et al., 1996, 2007; Ren et al., 2001). 
Contacts with Tyr181/Tyr188 are not very important for inhibitor binding if an 
inhibitor is flexible and can balance the loss of this important interaction by 
forming interactions with other amino acids (Tyr183, for example). In this case, 
this mutation will have a minor effect on the inhibitor activity of the compound. 
For example, nevirapine is 100 times less active against reverse transcriptase 
when it has the Y181C mutation, whereas efavirenz activity is less affected 
(Das et al., 2008; Ren et al., 2001). 
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The K103N mutation. The Lys103Asn mutation is the most common muta-
tion that leads to resistance against NNRTIs (Cheung et al., 2004) and confers 
resistance to a wide range of NNRTIs. It is also frequently associated with 
transmitted resistance to NNRTIs. The exact molecular mechanism of resistance 
is not completely understood. Lys103 forms hydrogen bonds with only a few 
inhibitors (Esnouf et al., 1997) and does not interact with others. In the mutant 
enzyme, Lys is changed to Asn, and it was proposed that in unligated enzyme 
Asn can form a hydrogen bond with Tyr188, thus stabilizing the unligated en-
zyme’s conformation and preventing the formation of the NNRTI binding 
pocket (Das et al., 2007; Hsiou et al., 2001; Lindberg et al., 2002; Maga et al., 
1997; Ren et al., 2000; Rodríguez-Barrios and Gago, 2004). The second genera-
tion NNRTIs are active against the K103N mutant; however, the exact mecha-
nism that allows them overcome its resistance is unknown. One possible expla-
nation is that these NNRTIs can make additional contacts with Asn103, which 
has been shown for GW4511 (Chan et al., 2004; Ren et al., 2008). It has also 
been demonstrated that etravirine can destroy the Asn103-Tyr188 interaction 
(Das et al., 2004; Rodríguez-Barrios et al., 2005). 
Mutations of L100I/V106A/V108I. These amino acids constitute the hydro-
phobic core of the NNRTI binding pocket. The main effect of these mutations is 
to change the Tyr181 (or Tyr188) position in reverse transcriptase and disrupt 
its aromatic ring-stacking interactions with NNRTIs (Ren et al., 2004, 2007). 
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STATE OF THE ART AND DEFINITION OF TASKS 
Antiretroviral drug is a compound that inhibits replication cycle and propaga-
tion of a retrovirus (in almost all cases HIV-1). Two main approaches are used 
in antiretroviral drug discovery; both of them were applied in studies presented 
in this thesis. 
The first one is a traditional trial-and-error method that relies on testing of 
many different (mostly random) compounds for their antiretroviral activity. 
This approach is time-consuming and not very fruitful. However, it holds a 
promise for discovery of inhibitors, which could have previously undiscovered 
mechanism of action. To increase the probability of such finding the library of 
compounds, that are analyzed, generally needs to be very large. At this case the 
method of choice is high-throughput screening by use of automated work-
stations. The required equipment and materials (including library of com-
pounds) are often beyond the reach of academic research groups. Nevertheless 
the same approach can be used by screening of smaller sets of compounds, 
though one should expect that chances for discovery of hits, which could subse-
quently be optimized to efficient inhibitors, is accordingly much lower. 
The second way to find novel inhibitors is a rational drug design 
(Menéndez-Arias and Gago, 2013). This approach requires knowledge of 
molecular mechanisms of a viral life cycle. Rational drug design relies on a 
defined drug target which is well studied and directly linked to a disease (or in 
case of viruses, essential for virus propagation). The initial library of com-
pounds is, again, very large but the difference is that this needs not to be real 
library. Thus, in the beginning, thousands or millions of compounds are virtu-
ally screened for their ability to bind and change the function of the drug target. 
This results in shortlisted compounds. Only compounds, selected in this screen, 
should be verified for their antiretroviral activity experimentally. Theoretically, 
the hit discovery rate based on such method could be higher but the diversity of 
discovered compounds are limited to the known paradigm. Other limitations of 
this approach is that virtual screening is not always as reliable as a real 
screening and number of promising compounds could be missed (false negative 
results). Similarly, number of compounds with no activity are likely to occur at 
the top of the hit list (false positive results). Thus, virtual screening is as good as 
good is the algorithm. Too stringent algoritms, which may result in too many 
false negative results, have therefore their limitation. In contrast, it is relatively 
easy to eliminate false positive hits in subsequent assays. Thus, even pre-
selected library will contain number of inactive compounds and the true hit (or 
lead) compound may even not be present in the hit list. Instead it may be hidden 
somewhere “close in chemical space”. 
Currently, there are many classes of compounds targeting different stages of 
HIV-1 life cycle (viral entry, reverse transcription, integration into the host 
DNA, particle maturation and others) (Pau and George, 2014). Many of them 
are clinically approved compounds and thanks to them HIV-1 infection, once 
universally lethal, has been converted to the chronic infection. Surely, this has 
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somewhat decreased the need for new anti-HIV-1 drugs. Nevertheless, HIV-1 
still represents exteremly important pathogen (and remains the most common 
killer among viruses infecting humans); thus it is likely short-sighted to con-
clude that fight with this virus is over.  
The most part of this thesis is devoted to the development of new reverse 
transcriptase inhibitors – both NRTIs and NNRTIs. Reverse transcriptase inhib-
itors are very important in antiretroviral therapy as they proved to inhibit HIV-1 
replication very efficiently. In addition, NNRTIs are very specific to HIV-1 and 
thus have comparably low toxicity. Reverse transcriptase itself and the reaction 
it catalyzes is very well studied: this makes the process of finding the candidates 
for testing more straightforward and reliable. Furthermore, several crystal 
structures of a wild-type and drug-resistant forms of reverse transcriptase are 
solved. This allows use of virtual screening for NNRTIs capable of inhibiting 
HIV-1 and its mutants resistant to the known NNRTIs. Hits from such screens 
may thus have higher genetic barrier to resistance and/or other propertis much 
needed for improvement of antiretrovirus therapy (long in vivo half-lifes, for 
example). Finally, even inhibitors which never reach clinical development 
(much less clinical use), teach us something new about virus and possibilities to 
inhibit it. Indeed, the 30 antiretroviral drugs represent just very small tip of 
iceberg compared to thousands compounds found to affect, at least to a certain 
extent, HIV-1 infection and millions of compounds lacking such property. 
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AIMS OF THE CURRENT STUDY 
The main aim of this work was to find novel inhibitor(s) of HIV-1 replication 
from groups of compounds previously not tested for antiretroviral activities. 
Thus, such compounds would have novel (for HIV-1 inhibitor) folds. We were 
looking for compound(s) that would simultaneously be non-toxic to cells and 
highly active against wild-type and, preferably, mutant forms of the virus. 
However, this was not the absolute requirement; we were also looking for hit 
compounds with unique folds that could be subsequently modified to obtain 
more active and less toxic leads. To accomplish this aim we had to: 
 
1. Develop and take into use a fast, safe and reliable system for screening com-
pounds with possible antiretroviral activity; 
 
2. Screen three different groups of compounds for their antiretroviral activity. 
The compounds belonged to: 
I. acyclic thymine nucleoside analogues 
II. bimorpholines and their derivatives 
III. saccharide hydrazones; 
 
3. Experimentally verify the results of the previous in silico screening (García-
Sosa et al., 2011) and reveal whether the in silico selected compounds represent 
promising anti-HIV-1 hits. Upon finding such compound it became important to 
identify the active component of the original sample. By this we also aimed to 
provide experimental verification whether novel and potent HIV-1 inhibitors 
can be developed using this drug design strategy. 
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RESULTS AND DISCUSSION 
 
1. Development of a new screening system for testing the 
antiretroviral activities of compounds (unpublished) 
In the early stages of this study, the conditions needed for the use of infectious 
HIV-1 were not available in our institute. To overcome this obstacle, a simple, 
efficient and safe assay using HIV-1-based virus-like particles (VLPs) was 
designed. The VLPs were produced using a modified ViraPower Lentiviral 
Expression System (Invitrogen) (Figure 8). To produce such particles, 4 plas-
mids are required:  
1. The pLenti6/V5-D-TOPO plasmid, which contains modified left and right 
LTRs and other HIV-1 regulatory sequences. These sequences enable the 
mRNA that is synthesized from this plasmid to be packaged into the VLPs 
and, importantly, to be reverse-transcribed and integrated into cells infected 
with such VLPs. This plasmid (and its mRNA, packaged into the VLP) 
contains sequences for the expression of both a blasticidin resistance marker 
and a reporter gene. 
2. Three plasmids with helper functions. Two of them provide structural and 
regulatory proteins and HIV-1 enzymes in trans. The pLP1 plasmid en-
codes the gag/pol protein, and the pLP2 encodes the Rev protein. The third 
plasmid, pLP/VSV-G, encodes the envelope G glycoprotein from vesicular 
stomatitis virus, which was used to pseudotype the formed particles (it also 
serves as an antireceptor and a fusion protein for VLP entry into infected 
cells). 
 
These four plasmids together are transfected into the 293FT cell line, resulting 
in the production of VLPs. These particles contain both HIV-1 enzymes (re-
verse transcriptase, integrase, protease) and mRNA produced from the modified 
pLenti6/V5-D-TOPO plasmid. When VLPs infect cells (generally we used 
U2OS cells for infection), this mRNA is reverse transcribed, and its corre-
sponding cDNA is integrated into the cell genome, from which the antibiotic 
resistance and reporter protein genes are expressed (Figure 8). 
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Figure 8. Schematic representation of ViraPower Lentiviral Expression System 
(Invitrogen) 
 
 
We have introduced two main changes in ViraPower Lentiviral Expression 
System: changed the reporter gene in the pLenti6/V5-D-TOPO plasmid and 
introduced point mutations in the gag/pol gene in the pLP1 plasmid (Figure 9). 
1. In our first experiments (article I and II), we used VLPs with EGFP reporter 
genes and performed colony-formation assays to evaluate the antiretroviral 
activities of the tested compounds. However, this method is time-consuming 
(10–14 days are required for colonies to form). Therefore, we replaced the 
EGFP-encoding sequence in the pLenti6/V5-D-TOPO-EGFP plasmid with a 
Gaussia luciferase-encoding sequence and obtained the pLenti6/V5-D-
TOPO-GLuc plasmid (Figure 9A). Gaussia luciferase is produced only from 
synthesized (but not necessarily integrated) cDNA; thus, the activity of this 
reporter depends on the efficiency of reverse transcription. This assay is very 
sensitive and allowed us to determine the antiretroviral activity of each of 
the compounds by measuring Gaussia luciferase activity at 2 days post-
infection, which was faster and also more accurate than the previous method. 
2. One of benefits of using a VLP-based system is that this system is essentially 
free of reversions (mutations do occur during reverse transcription but 
because no progeny are made and the experiments are limited to a single 
round of reverse transcription, the mutations do not become dominant). This 
makes VLPs an ideal tool for the incorporation of reverse transcriptases 
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containing resistant-associated mutations. To do this, we introduced point 
mutations in the gag/pol gene in the pLP1 plasmid (Figure 9B). The 
mutations were selected from those known to produce resistance against the 
NNRTI nevirapine (and a number of other NNRTIs). In total, three mutant 
variants of reverse transcriptase were obtained and packed into VLPs: 
K103N, Y181C, and a double-mutant with both K103N and Y181C 
changed. These tools were used to analyze the specificity of each inhibitor 
and their individual abilities (or lack of it) to inhibit NNRTI-resistant reverse 
transcriptase. 
 
 
Figure 9. Schematic representation of plasmids used in the assay: (A) pLenti6/V5-D-
TOPO-EGFP and pLenti6/V5-D-TOPO-GLuc plasmids, (B) pLP1 plasmids: wild type 
and with mutations (pLP1 K103N, pLP1 Y181C, pLP1 dual). 
 
 
2. Antiretroviral activities of novel acyclic thymine 
nucleoside analogues (article I) 
Acyclic nucleoside analogues are analogues of cellular nucleosides; they con-
tain a normal (or, sometimes, modified) nitrogenous base and an acyclic sugar 
moiety. Such compounds can have antiviral activity. In the cell, they may be-
come phosphorylated to their corresponding triphosphate forms and act as 
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chain-terminating inhibitors (in other words, they act as NRTIs for HIV-1). The 
most famous examples of acyclic nucleoside analogues include acyclovir and 
penciclovir (guanine derivatives, herpes simplex virus inhibitors) (Boyd et al., 
1987; Elion et al., 1977), ganciclovir (guanine derivative, cytomegalovirus 
inhibitor) (Mar et al., 1983), tenofovir (adenosine monophosphate analogue, 
HIV-1 and hepatitis B virus inhibitor) (Balzarini et al., 1993) and several others 
(De Clercq and Field, 2006). 
In this study, five acyclic thymine nucleoside analogues were synthesized 
(article I, schemes 1–4) and analyzed for their antiretroviral activities. First, the 
toxicity of each compound was measured using an MTT cell viability assay. 
This assay revealed that the synthesized compounds were not toxic at the high-
est concentration applied (50 µM) (article I, Table 1 and this thesis, Table 2). 
Then, the antiretroviral activity of each compound at 50 µM was analyzed using 
HIV-1 VLPs in a colony formation assay. All tested compounds had some 
inhibitory effect, reducing colony formation by 45 – 63% compared to DMSO, 
which was used as a vehicle control (article I, Table 2 and this thesis, Table 2). 
 
 
Table 2. Biological properties of novel acyclic thymine nucleoside analogues 
Compound Toxicity assay, HeLaa 
50 µM 
Antiretroviral activityb 
50 µM 
DMSO ( negative control) 100 100 
6a 97 60 
6b 104 48 
6c 110 52 
6d 108 45 
6e 103 63 
Lam ND 9 
AZT ND 3 
a cell viability, percentage from negative control, b efficiency of colony formation, percentage 
from negative control, ND – not determined. 
 
 
As these compounds were not toxic, it served as indication that they had direct 
effect on infectivity of HIV-1 VLPs. The exact mechanism of their actions was 
not studied, but presumably they can act as chain-terminators (which is a com-
mon mechanism of acyclic nucleoside analogues). Another possibility would be 
that they inhibit the integration of proviral cDNA; in the absence of integration, 
colony formation would have been inhibited as well. However, this is much less 
likely, as the tested compounds share no similarities with known HIV-1 inte-
grase inhibitors. It should be also noted that attempts at finding the rate-limiting 
step restricting the potency of these compounds were made, but they were not 
successful. Indeed, the lack of prominent inhibition of these compounds may 
result from poor cellular uptake, inefficient conversion of these prodrugs into 
active (triphosphate) forms or the inability of HIV-1 reverse transcriptase to use 
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them. Obtaining these compounds in triphosphate forms was a complicated 
endeavor, which hampered their use in the cell-free replication assay. The ex-
pression of the thymidine-kinase of herpes simplex virus (an enzyme known to 
phosphorylate many acyclic nucleoside) had no effect on the potencies of these 
compounds. Thus, the rate-limiting step remained unknown. Regardless of their 
individual natures and the mechanisms of action of the members of this class of 
compounds, their detected antiviral effects were not prominent enough to war-
rant subsequent studies.  
 
 
3. Antiretroviral activity of bimorpholines  
(article II and unpublished data) 
Morpholine is a simple heterocycle. The morpholine moiety is a structural motif 
that is found in different natural products and therapeutically active compounds 
and has been extensively used in drug design (Wijtmans et al., 2004). Examples 
of morpholine-containing compounds include the antidepressant drug reboxe-
tine (Wong et al., 2000), the neurokinin 1 receptor antagonist aprepitant (Patel 
and Lindley, 2003) and several others. Also, morpholine-containing compounds 
have been shown to have antiviral activity. They act as potent non-nucleoside 
allosteric inhibitors of HCV polymerase (Beaulieu et al., 2004; Hirashima et al., 
2007) and HIV-1 integrase inhibitors (Gardelli et al., 2007). 
In this study, six compounds representing bimorpholine and its derivatives 
were synthesized (article II, Figure 1, schemes 1–4 and this thesis, Table 3), and 
their biological activities were studied. I will focus on the toxicity profiles and 
antiretroviral activities of compounds 1 and 8–11. Using an MTT cell viability 
assay, it was found that these compounds were generally not toxic at a 50 µM 
concentration. However, the results for compound 1 were somewhat controver-
sial, as its toxicity depended on cell type and even on the amount of cells pre-
sent (confluency) at the time of treatment (article II, Tables 1 and 2). This 
somewhat confusing data was one of the reasons why in subsequent studies the 
MTT method was substituted with the more sensitive and reliable xCELLigence 
assay. The controversy regarding the toxicities of the compounds did not, how-
ever, affect the outcome of the anti-retroviral activity assay. When applied at a 
50 µM concentration, none of the compounds were active in the HIV-1 VLP-
based colony formation assay (this thesis, Table 3). Thus, it should be 
concluded that the analyzed compounds were unable to inhibit HIV-1 reverse 
transcriptase or integrase. 
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Table 3. Biological properties of bimorpholines 
Compound Structure Toxicity 
assay, 
HeLaa 
50 µM 
Antiretroviral 
activityb 
50 µM 
DMSO (negative control) – 100 100 
1 101 67 
8 
 
90 91 
9 
 
98 72 
10 
 
91 63 
11 
 
96 69 
Lam – ND 9 
a cell viability, percentage from negative control, b efficiency of colony formation, percentage 
from negative control, ND – not determined. 
 
 
4. Antiretroviral activity of  
saccharide hydrazones (article III) 
Hydrazones containing heterocycles and sugar moieties can be considered acy-
clic nucleoside analogues, and such types of compounds have been shown to 
have antiviral activity. For example, they can inhibit herpes simplex virus type-
1 (HSV-1) and hepatitis A virus replication (Abdel-Aal et al., 2008; Rashad et 
al., 2009). Moreover, some hydrazone derivatives have antiretroviral activity: 
they inhibit HIV-1 reverse transcriptase RNase H and/or DNA polymerase 
activities (Arion et al., 2002; Distinto et al., 2012; El-Sayed et al., 2009; 
Himmel et al., 2006). 
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Table 4. Biological properties of saccharide hydrazones 
Compound Monosaccharide Toxicity assay, U2OSa 
1 mM 
Antiretroviral activityb 
1 mM 
DMSO (negative 
control) 
– 100 100 
4 L-arabinose 108 131 
5 106 96 
6 108 11 
7 D-galactose 102 117 
8 106 126 
9 109 136 
10 D-mannose 100 101 
11 94 93 
12 100 122 
13 D-ribose 112 93 
14 115 115 
15 113 101 
16 L-rhamnose 110 95 
17 115 133 
18 108 117 
19 2-deoxy-D-
ribose 
105 121 
20 102 150 
21 104 64 
nevirapine – ND 0,03 
a cell viability, percentage from negative control, b Gaussia luciferase activity, percentage from 
negative control, ND – not determined. 
 
 
A rather large set of novel compounds (18 in total) with different sugar moieties 
was synthesized, and their biological activities were tested (article III, Table 1 
and this thesis, Table 4). The xCELLigence cell viability test revealed that these 
compounds were very well tolerated by cells, and no toxicity was observed even 
at 1 mM concentrations. The antiretroviral activities of these compounds were 
tested using HIV-1 VLPs, which carried RNA molecules capable (when re-
verse-transcribed) of expressing the Gaussia luciferase reporter. It was found 
that only two compounds (6 and 21) inhibited the infectivity of HIV-1 VLPs. Of 
these, compound 21 was a very weak HIV-1 inhibitor: when applied at 1 mM, it 
reduced the Gaussia luciferase signal to 64 % relative to the vehicle control and 
thus has an IC50 > 1 mM. In contrast, when compound 6 was applied at a 1 mM 
concentration, it reduced the Gaussia luciferase signal to 11 % of that from the 
samples treated with vehicle control (this thesis, Table 4). However, when this 
compound was used at lower concentrations, its inhibitory effect was dramati-
cally reduced. The IC50 for this compound was ≈ 400 µM, which is much 
higher than that of the typical acyclic nucleosides (article I) or non-nucleoside 
inhibitors that are described in article IV. Therefore, the anti-HIV-1 properties 
of these compounds were not studied further, and their mechanisms of action 
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remain unknown. However, as these compounds were absolutely not toxic, it 
could be assumed that their effects on the infectivity of HIV-1 VLP were direct. 
 
 
5. Non-nucleoside reverse transcriptase  
inhibitors and in silico screening (article iv) 
5.1 Cytotoxicity and antiretroviral activity of  
16 compounds selected using in silico screening 
The starting point of the work was to develop novel NNRTIs using a previously 
described in silico screening technique (García-Sosa et al., 2011). Two ap-
proaches were used in this in silico screen: i) The compounds were ranked ac-
cording to their abilities to bind both wild-type and Y181C drug-resistant HIV-1 
reverse transcriptases, and ii) the compounds were screened for their abilities to 
bind several antitargets (i.e., biomolecules, the binding to which can cause un-
desired side-effects). This combined approach allowed us to find possible in-
hibitors of HIV-1 reverse transcription and to simultaneously roughly predict 
their metabolic interactions. Not surprisingly, the top hits resulting from this 
screen were known antiretroviral compounds, but the hit list also contained a 
large number of compounds antiretroviral properties of which were not known. 
To analyze whether any of these compounds had the ability to suppress HIV-1 
infection (article IV, Figure 1), 16 compounds with diverse chemical structures 
were experimentally tested for their antiretroviral activities. These compounds 
were purchased, and their biological properties were determined. Each of the 16 
compounds was screened for toxicity (using the xCELLigence cell viability 
test), antiretroviral activity (using HIV-1 VLPs with Gaussia luciferase reporter 
gene) and the ability to inhibit a cell-free reverse transcription reaction (enzy-
matic reverse transcription assay). 
Cell viability analysis revealed that at 50 µM compounds 1, 14 and 15 were 
highly toxic; moderate toxicity was detected for compounds 4, 8, 11 and 16 
(article IV, Figure 2A, Table 1). For these compounds, an analysis was also 
performed using a 5 µM concentration, revealing no detectable toxicity at that 
concentration (article IV, Figure 2B, Table 1). Accordingly, in subsequent ex-
periments using HIV-1 VLPs, non-toxic concentrations of each compound were 
applied, except for the moderately toxic compounds, which were tested at both 
analyzed concentrations (thus, 50 µM was used for compounds 2–13 and 16, 
and 5 µM was used for 1, 4, 8, 11, 14, 15, and 16). 
When tested against HIV-1 VLPs, compounds 11, 13, and 16 showed mod-
erate activities, and compound 8 was highly active: compound 8 decreased 
Gaussia luciferase signal to 5.2% of that of the vehicle control when it was 
applied at a 50 µM concentration and to 20% of the control when it was applied 
at a 5 µM concentration (article IV, Figures 2C and 2D, Table 1). Further analy-
sis revealed that the IC50 for compound 8 was 0.33 ± 0.07 µM (article IV, 
figure 3A, table 2), which is well below any of the compounds that were ana-
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lyzed in studies I–III and only 10 times higher than the activity of the licensed 
NNRTI nevirapine, which was used as a positive control (its IC50 in the same 
test was 0.043 ± 0.007 µM) (article IV, Table 2). Thus, compound 8 was con-
sidered to represent a potential NNRTI with relatively high activity. 
The efficacies of compounds are often seriously affected by their abilities to 
enter cells. To determine whether any of the compounds were more active in the 
absence of this obstacle, all of the compounds were tested in a cell-free enzy-
matic reaction. As NNRTIs are not particularly efficient in inhibiting the type of 
reaction that was used in this study (see above), each compound was tested at 
high concentrations (200 µM and 50 µM). It was found that at 200 µM only 
compounds 1, 2, 8, and 12 were able to inhibit the activity of HIV-1 reverse 
transcriptase (article IV, Figure 4A, Table 1), whereas at 50 µM only compound 
8 was active (article IV, Figure 4B, Table 1). The IC50 for compound 8 in this 
cell-free reaction was much higher than in the cell-based assay; it was 105.7 ± 
30 µM (article IV, Figure 3B, Table 2), which is about 100 times higher than 
the IC50 of nevirapine (0.92 ± 0.15 µM) in the same assay (article IV, Table 2). 
Nevertheless, this assay clearly confirmed that compound 8 acts as an NNRTI, 
as only compounds belonging to this class of inhibitors should be active in this 
cell-free assay. Compounds 1, 2 and 12 probably possess some NNRTI activity 
as well, but such activity was clearly lower than that of compound 8. None of 
these compounds showed detectable activities in a cell-based assay, indicating 
that their anti-HIV-1 activities were hampered by intrinsic cytotoxicity (com-
pound 1) and/or by an inability to enter cells (the most likely explanation for the 
lack of activity in the cases of compounds 2 and 12). 
Thus, three performed tests revealed that only compound 8 represents a po-
tential HIV-1 inhibitor. 
 
 
5.2 Chemical characteristics of compound 8.  
Antiretroviral activity of compound 8 (purified from the  
commercial sample) and its separated isomers 
Chemically, compound 8 is a diaryltriazine derivative. It is a symmetrical mole-
cule, and it binds to HIV-1 reverse transcriptase the same way after a 180° flip. 
It has a chiral center and exists in two stereo-isomeric forms. Diaryltriazine 
derivatives can have anticancer activities (Menicagli et al., 2004), antibacterial 
activities (Kumar and Menon, 2009; Lübbers et al., 2000; McKay et al., 2006; 
Srinivas et al., 2005), and antifungal activities (Ghaib et al., 2002). Further-
more, some diaryltriazine derivatives act as potent NNRTIs (Ludovici et al., 
2001), although for compound 8, or even compounds with similar structures, 
antiretroviral activity has not been previously shown. 
To determine which stereoisomer of compound 8 is responsible for the inhi-
bition of HIV-1 replication, a large sample of compound 8 was purchased. First, 
its purity was tested using HPLC (article IV, Figure 5). It turned out that com-
mercial samples of compound 8 (both the one used in the first screen and the 
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one purchased later) were mixtures of at least four different chemicals, although 
compound 8 was indeed the main component of the mixture (about 89% of the 
total mass of the sample). Three additional compounds (designated initially as 
x, y and z) together constituted about 11% of the mass of the sample. To get rid 
of the additional compounds, compound 8 was purified by HPLC to homogene-
ity; the fractions containing the x, y and z compounds were also collected (note 
that it was impossible to separate compounds x and y from each other, so they 
were collected as a mixture of compounds designated x/y). Then, compound 8 
was separated into two stereo-isomers using an HPLC chiral column. 
Next, the antiretroviral activities of compound 8 (purified from the commer-
cial sample) and its two separated stereo-isomers were analyzed. To our sur-
prise, the activity of purified compound 8 was drastically lower (detectable only 
at 50 µM, article IV, Figure 6) than that of the original (non-purified) mixture. It 
was impossible to detect whether this residual activity was due to the true anti-
HIV-1 activity of the purified compound or whether it was caused by residual 
impurities and/or toxic effects of the compound (article IV, Figure 2A). Corre-
spondingly, neither stereo-isomers of compound 8 had clear anti-HIV-1 activity 
(data not shown). Thus, it become clear that compound 8, a compound revealed 
by an in silico screen and the major component of the purchased sample, could 
not be the true HIV-1 inhibitor; instead, the antiretroviral activity of the sample 
belonged to some additional component(s). It was also clear that, as the addi-
tional components together consisted of approximately 11% of the mass of 
sample, the anti-HIV-1 activity of an active component(s) should be much 
higher than that of the mixture. In light of these data, it would have been inter-
esting to re-visit the data produced by compounds 1, 2 and 12, all of which 
demonstrated some NNRTI activity in the cell-free assay. If these compounds 
are mixtures (which is quite possible) then their anti-HIV-1 activities may also 
belong to minor component(s); these may be more potent and/or less toxic as 
initial compounds. However, taking into account the amount of work that was 
required to identify and synthesize the active component of compound 8 (see 
below), such studies were not performed. 
 
 
5.3 Identification of the active component(s)  
from the initial sample of compound 8 
To test the hypothesis that the antiretroviral activity of compound 8 belongs to 
some other minor component(s) of the initial mixture, we analyzed the an-
tiretroviral activities of: i). the compound 8 before purification (initial sample 
together with impurities), ii) compound 8 after purification, iii). impurity z, and 
iv). impurity x/y from the initial sample. For this, each compound was applied 
at its maximum possible concentration (note that the exact concentrations of x/y 
and z could not be calculated, as neither their structures nor the ratio of x/y in 
the mixture were not known). First of all, toxicity testing was performed; it 
revealed that only the x/y mixture was non-toxic, as the other compounds 
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showed moderate toxicities (data not shown). In VLP-based activity assay, the 
x/y mixture had the highest antiretroviral activity; this activity was even higher 
than the activity of the compound 8 sample before purification. At the same 
time, both purified compound 8 and the z impurity had moderate antiretroviral 
activities (article IV, Figure 6). 
This experiment confirmed that compound 8 itself was not the active com-
ponent of the initial sample. Instead, most (if not all) of the sample’s antiretrovi-
ral activity belonged to components x or/and y. Hence, our next goal was to 
determine the active compound(s) present in the initial sample. 
To do this, two approaches were used:  
1. An analysis of the methods that were possibly used for the synthesis of 
compound 8.  
2. An analysis of the x/y fraction using combined high-resolution MS and 
NMR approach. 
 
 
5.4 The analysis of the methods that were possibly  
used for the synthesis of compound 8 
5.4.1 Identification of compounds 17, 18, and 19 
The molar masses of compounds x, y, and z were estimated using HPLC analy-
sis. It was assumed that compounds x, y, and z could be “side” products or 
intermediates of compound 8 synthesis. As there was no information on how 
exactly compound 8 was produced, all possible synthetic routes were analyzed. 
Based on this, possible candidates for x, y, and z were proposed. To maintain 
consistent numbering, they were correspondingly designated as compounds 17, 
18, and 19 (article IV, Table 3). All of these compounds were similar to com-
pound 8; they each shared the same diaryltriazine core but had somewhat dif-
ferent functional groups. When compounds 17, 18, and 19 were docked into the 
NNRTI binding pocket of HIV-1 reverse transcriptase (similarly to what was 
done in the previous article (García-Sosa et al., 2011)), it was predicted that 
compound 18 would be the most potent inhibitor, that compound 19 would be 
less potent and that compound 17 would be the least potent (article IV, Table 3). 
 
 
5.4.1 Toxicity and antiretroviral activity of compound 8 synthesized in-house 
The synthesis route that was most likely used for the synthesis of compound 8 
was applied to obtain a larger amount of the compound and larger amounts (as 
was hoped) of the impurities x, y and z (note that by this time we had exhausted 
the world supply of compound 8, and no more could be purchased from any 
known source). It should be noted that while the synthesis of compound 8 was 
highly efficient, the final product was very clean and did not contain impurities 
similar to x, y, or z (thus, synthesizing a dirty compound is sometimes a prob-
lem). As could be expected, synthesized compound 8 and its two stereo-isomers 
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behaved similarly to purchased and purified compound 8 and its purified stereo-
isomers. Again, the activities against HIV-1-based VLPs of both compound 8 
and its isomers were rather low (IC50 (comp 8) = 16.0 ± 3.5 µM; IC50 (isomer 
1) = 18.2 ± 5.2 µM; IC50 (isomer 2) = 32.0 ± 12.0 µM) (article IV, Figure 7, 
Table 2 and data not shown). In addition, synthesized compound 8 and its iso-
mers did not inhibit an in vitro, cell-free reverse transcription reaction (data not 
shown). These data indicate that compound 8 has some anti-HIV-1 activity of 
its own, but it was too low to be detected in the cell-free assay. 
 
 
5.4.2 Toxicity and antiretroviral activity of  
compounds 17, 18, and 19 synthesized in-house 
For the next step, compounds 17, 18, and 19 were synthesized. Compounds 17 
and 19 were not active in the HIV-1-based VLP assay (article IV, Table 2). As 
such, our attention was focused on compound 18. It was determined that this 
compound was rather toxic (a first indication that it is not identical to impurity 
y), but it was certainly the only active compound synthesized in-house (which 
was consistent with in silico predictions). Using HIV-1-based VLPs, its IC50 
was determined to be 2.5 ± 0.3 µM, and its CC50 (in these experiments, the 
U2OS cell line was used) was 42.2 ± 5.6 µM. Hence, its SI (selectivity index, 
the ratio CC50/IC50) was about 17 (article IV, Figure 8A, Table 2). When the 
experiment was performed using full infectious virus, compound 18 was also 
found to be active, with IC50 = 5.6 ± 1.1 µM, CC50 = 57 ± 22 µM (determined 
for TZM-bl cells) and SI = 10 (article IV, Figure 8B, Table 2). Finally, it inhib-
ited reverse transcription in a cell-free reaction (IC50 = 116 ± 12 µM) (article 
IV, Figure 8C, Table 2) but lacked activity against HIV-1 VLPs carrying mutant 
forms of reverse transcriptase resistant to the known NNRTI nevirapine (3 types 
of mutants were used: with K103N mutation, with Y181C mutation or with both 
of these mutations together). 
Taken together, all of these data confirmed that compound 18 is a directly 
acting antiviral and NNRTI and that its binding to its target is affected by 
known anti-NNRTI resistance mutations.  
 
 
5.4.3 Analysis of compound 18 binding mode 
Computational analysis showed that compound 18 binds to reverse transcriptase 
similar to the binding modes of approved NNRTIs (etravirine (Das et al., 2004) 
and rilpivirine (Das et al., 2005; Pauwels, 2004) (article IV, figure 9). It binds 
deeply into the tight, closed NNRTI binding pocket. It has a flexible structure, 
which allows it to adopt different conformations and therefore it can bind re-
verse transcriptase in several modes. Compound 18 forms the following inter-
actions with the NNRTI binding pocket:  
1. π-π stacking interactions with the aromatic residues Tyr 181, Tyr 188, Trp 
229, and Phe 227; 
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2. hydrophobic interactions with the non-polar residues Leu 234, and Val 179;  
3. hydrogen bonds with the charged residues Lys 101 and Glu 138.  
 
The important features that differentiate compound 18 from other diaryltriazine 
derivatives with NNRTI activities (Ludovici et al., 2001) include the following:  
1. its charged ammonium group, which strongly interacts with the Glu 138 
carboxylic group;  
2. its molecular symmetry, which allows it to bind to the NNRTI binding 
pocket tightly after a 180° flip.  
 
However, despite the flexible structure of compound 18, mutations at positions 
103 and/or 181 still completely inhibited its anti-HIV-1 activity, presumably by 
preventing (or weakening) its binding to its target. 
 
 
5.4.4 Compound y was predicted incorrectly 
Although compound 18 was the most potent of the compounds synthesized in-
house, it was also obvious that it is not identical to impurity y; it is more toxic, 
and most importantly its activity (IC50 = 2.5 ± 0.3 µM) was not sufficient to be 
responsible for the high antiretroviral activity of the initial compound 8 sample 
(IC50 = 0.33 ± 0.07 µM). As the latter contained only a small fraction of the x/y 
impurity, the structure of one of the compounds (x or y) must have been pre-
dicted incorrectly. To test this hypothesis, we compared HPLC chromatograms 
for the x/y fraction from the initial compound 8 sample (two compounds in one 
peak, impossible to separate) and for an artificial 17/18 mixture (two clearly 
separated peaks). At the same time, the peak of compound x was identical to the 
peak of compound 17, whereas the peaks of compound y and compound 18 
were different (data not shown). Thus, we concluded that the structure of com-
pound x (17) was predicted correctly, whereas the structure of compound y (18) 
was predicted incorrectly. It was also clear that all antiviral activity of the x/y 
mixture belonged to compound y because compound 17 (corresponding to x) 
lacked antiretroviral activity. This indicates that the true compound y should 
have an IC50 that is considerably lower than 0.33 µM (the IC50 of the initial 
sample of compound 8). 
 
 
5.5 The analysis of the x/y fraction using combined  
high-resolution MS and NMR approach 
5.5.1 Identification of compound 20 
Because the amount of the x/y impurity in the initial sample of compound 8 was 
very small (only ≈ 0.2 mg of material was collected), a combined high-resolu-
tion MS and NMR approach was applied to resolve the structure of compound 
y. In this experiment, synthesized compound 17 was used as a reference for the 
60 
 
x component of the x/y mixture. First, the exact molar mass of y was measured 
using LC-ESI-QTOF-MS, and from this its molecular formula, C17H18N5O, was 
determined. Then, the structures of compounds from the x/y mixture were ana-
lyzed by NMR, which confirmed the presence of oxygen instead of nitrogen (as 
in compound 18). Based on this, a structure for y, now designated compound 
20, was proposed (article IV, Table 3). Compound 20 is very similar to com-
pound 18, and they have identical molar masses; the only difference is that the –
NH2 group of compound 18 is substituted with an –OH group in compound 20. 
According to computational analysis, compounds 18 and 20 bind to the NNRTI 
binding pocket in the same way, with the only difference being that compound 
20 binds to the NNRTI binding pocket more strongly (article IV, Figure 10). In 
addition, compound 20 exists in several tautomeric forms and protonation 
states, which helps the compound to adapt to the protein. 
 
 
5.5.2 Toxicity and antiretroviral activity of compound 20 synthesized in-house 
Compound 20 was synthesized in-house in quantities sufficient for the analysis 
of its biological properties. The analysis was, however, partly hampered by the 
fact that compound 20 was poorly soluble in DMSO (its highest possible con-
centration was 2.5 mM, compared to >10 mM for compound 18 and the other 
compounds tested in this study). Thus, the highest concentration we could apply 
in our cell culture experiments was 12.5 µM (in order not to exceed a 0.5% 
concentration of DMSO in culture media; it was found that DMSO above this 
concentration affects cell viability). At 12.5 µM, compound 20 was clearly non-
toxic, and it is likely that it would also be tolerated at considerably higher con-
centrations. Most importantly, it was highly active in the HIV-1-based VLPs 
assay (IC50 = 0.067 ± 0.009 µM) and also against full HIV-1 (IC50 = 0.16 ± 
0.05 µM) (article IV, Figures 11A and B, Table 2). Taking into account that 
compound 20 was not toxic at the highest tested concentration (12.5 µM), its 
selectivity index values should be no less than 186 (for VLPs and U2OS cells) 
and 78 (for HIV-1 and TZM-bl cells). Compound 20 also inhibited reverse tran-
scription in cell-free conditions (IC50 = 55.1 ± 7.5 µM) (article IV, Figure 11C, 
Table 2). Despite its high activity, compound 20 was not active against HIV-1 
VLPs carrying a reverse transcriptase that was resistant to nevirapine (which 
had a K103N or Y181C mutation) (data not shown); however, surprisingly, it 
showed some activity against the dual mutant (with both K103N and Y181C 
mutations). This activity was, however, rather limited (IC50 = 8.0 ± 4.0 µM), 
indicating that the combination of mutations reduces the activity of compound 
20 by more than 100-fold (article IV, Figure 11D). 
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CONCLUSIONS 
 
This thesis summarizes results obtained during several studies dedicated to a 
search for new compounds capable of inhibiting HIV-1 infection. 
 
1. The developed HIV-1 VLP based assay was found to be fast and sensitive. 
The assay is also safe-to-use and can be used outside of BSL3 facilities needed 
for studies involving infectious HIV. The assay allows screening compounds for 
their ability to inhibit some particular stages of HIV-1 life cycle: reverse tran-
scription reaction and entry into the nucleus; also it can be modified for screen-
ing for integrase inhibitors. Another benefit of this system is that it allows test-
ing the activity of compounds against HIV-1 VLPs carrying mutant forms of 
reverse transcriptase. Such VLPs enable the confirmation of the mechanism of 
action of the inhibitors and allow us to analyze whether NNRTI-resistant repli-
cases are sensitive to new compounds. Finally and most importantly, in all cases 
where HIV-1 VLP based assay and the assay based on the use of infectious 
HIV-1 were used in parallel the results of these assays correlated with each 
other. If anything, the HIV-1 VLP based assay was somewhat more sensitive 
than assay based on use of wt virus. 
Currently, our laboratory provides the opportunity for different Estonian 
chemical research groups to test their compounds for toxicity and antiretroviral 
activity. Furthermore, simple and sensitive HIV-1 VLP based assay can be used 
by laboratories lacking BSL3 facilities. I believe this promotes the field of the 
development of antiretroviral compounds in Estonia. 
 
2. During these studies, several sets of compounds with presumable anti-HIV-1 
activities were analyzed. The experimental tests of these hypothesis yielded in 
different results. 
I. Each of the five analyzed acyclic thymine nucleoside analogues had minor 
antiretroviral activity. Thus, acyclic nucleoside analogues can act as 
antiretroviral compounds and probably share mechanism of action described 
for NRTIs.  
II. The least active group of compounds, analyzed in the presented studies, was 
the group of bimorpholines and their derivatives. None of these compounds 
had any detectable direct antiretroviral activity. In addition, these 
compounds were rather toxic, and their minor effects on the infectivity of 
HIV-1 VLPs can be attributed to their toxic effects on cells. 
III. None of eighteen studied novel saccharide hydrazones was toxic at a 1 mM 
concentration, and two of them had antiretroviral activity. This activity, 
however, was far lower than the activities found for the most potent 
compounds selected in studies I and IV (and more so compared to licensed 
anti-HIV-1 drugs). 
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3. Antiretroviral activities of compounds selected in the previous in silico 
screening (García-Sosa et al., 2011) were tested. None among 16 selected and 
tested compounds was a potent HIV-1 inhibitor indicating that most of these 
represented false-positive hits of in silico screen. One compound (number 8), 
however had a low antiretroviral activity. Search for compounds with structures 
similar to that of compound 8 resulted in several new compounds, 4 of which 
(compounds 17, 18, 19, and 20) were synthesized and experimentally tested. 
Out of these, compound 18 was moderately active while the activity of com-
pound 20 was comparable with the activity of the known NNRTI nevirapine. 
Unfortunately, neither of these compounds was able to efficiently inhibit HIV-1 
VLPs carrying certain forms of reverse transcriptase resistant against NNRTI 
drugs. This limits possible practical value of the compounds themselves. How-
ever, the set consisting from several compounds with similar structures but very 
different anti-HIV-1 activities, offers possibilities of in silico hit-to-lead optimi-
zation. Indeed, compounds 17, 18, 19, and 20 were also ranked according to 
their relative abilities to bind wild-type reverse transcriptase using in silico 
methods (the same approach was used when the initial set from 16 compounds 
were selected). The results of prediction fitted perfectly with the experimental 
data which additionally proves that we have developed a working algorithm for 
searching for HIV-1 NNRTIs which can be altered for purpose of lead-to-hit 
optimization. 
Thus, in silico prediction indeed revealed a structure that had some anti-
HIV-1 potency but that was clearly not optimal for this activity. However, in 
silico analysis clearly allowed for the narrowing down of chemical space when 
searching for compounds with high activities. 
Every year hundreds of articles describing new in silico methods and predic-
tions based on them are published. Such searches have not been limited to the 
prediction of novel HIV-1 inhibitors; large variety of pathogens and the diseases 
have been targeted. However, results of only very few of such screens have 
been verified experimentally. In this study we performed such verification and 
describe several problems that may be characteristic for this type of approach. 
Verification of theoretical data is important and is the only way to improve 
existing in silico methods and to finally find really potent inhibitor(s) (or other 
compounds with desired properties). 
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SUMMARY IN ESTONIAN 
Kui bioloog kohtab keemikut: HIV-1 inhibiitorite otsingul 
HIV on ohtlik virus, mis avastati eelmise sajandi 80-ndate alguses. Tollel ajal 
tähendas diagnoos “HIV-positiivne” nakatunutele sisuliselt surmaotsust. Nüüd, 
veidi rohkem kui 30 aastat hiljem, elavad HIV-positiivsed inimesed oluliselt 
kauem ja palju täisväärtuslikumat elu. Kõik see on saanud võimalikuks tänu 
ennenägematult ulatuslikele HIV-alastele uurimistöödele. Erakordselt põhjali-
kult on uuritud viiruse bioloogia eripärasid; välja on töötatud süsteemid viiruse 
tuvastamiseks organismis. Alates 1987-ndast aastast on loa kliiniliseks kasuta-
miseks saanud ligi 30 erinevat ühendit, mis jagunevad toimemehhanismide alu-
sel viide erinevasse klassi. Erinevatesse klassidesse kuuluvate inhibiitorite kom-
bineeritud kasutamine on kujunenud HIV-ga nakatunud patsientide ravimise 
aluseks. Samas, seoses viiruse suure muteerumisvõime ja osade (eriti vanemate) 
ravimite kõrge toksilisusega, on säilinud vajadus leida uusi ja paremaid (aktiiv-
semaid ja vähem toksilisi) toimeaineid. Seetõttu tegeleb meie töörühm, nagu ka 
sajad teised laborid üle maailma, uute retroviirus-vastaste ühendite otsinguga.  
Antud väitekirja põhieesmärgiks oli leida efektiivseid HIV-1 replikatsiooni 
inhibiitoreid, mis kuulvad kas nukleosiidsete (NRTI) või mittenukleosiidsete 
(NNRTI) pöördtranskriptaasi inhibiitorite hulka. Enne käesolevat uuringut ei 
olnud Eestis süstemaatiliselt tegeletud keemiliste ainete HIV-vastaste omaduste 
uurimisega ning puudus ka võimalus infektsioonilise HIV-1-ga koekultuuris 
töötada. 
Töö esimeseks eesmärgiks oli HIV-1 inhibiitorite analüüsi tarvis kiire, ohutu 
ja usaldusväärse süsteemi väljatöötamine. Selleks valisime HIV viirus-laadsetel 
osakestel (VLP) põhineva test-süsteemi, mida kasutasime alternatiivina tõelisele 
(infektsioonilisele) HIV-1 viirusele. Selle süsteemi loomiseks modifitseerisime 
lentiviirusel põhinevat ekspressioonivektorit nii, et see ekspresseeriks kergesti 
määratavat markervalku – Gaussia lutsiferaasi. See iseenesest lihtne täiendus 
tegi test-süsteemi palju kiiremaks ja tundlikumaks ning muutis selle kasutamise 
kergemaks. Lisaks sisestasime HIV-1 pol-geeni sisaldavasse ekspressiooni-
konstrukti NNRTI vastase resistentsusega seotud mutatsioone; see võimaldas 
meil analüüsida uuritavate keemiliste ainete toimet ravimiresistentsete repli-
kaaside suhtes. Tulemused, mis saadi selliseid HIV VLP-sid kasutades, korre-
leerusid infektsioonilist HIV-d kasutades saadud tulemustega; reeglina oli HIV 
VLP-de põhine süsteem infektsioonilisel viirusel põhinevast süsteemist isegi 
tundlikum.  
Järgmiseks eesmärgiks oli neid süsteeme kasutades uurida kolme erineva 
ühendite komplekti HIV vastast aktiivsust. Esiteks analüüsiti viie uudse mitte-
tsüklilise tümidiini nukleosiidi analoogi omadusi. Igal selle grupi ühendil tuvas-
tati madal retroviirus-vastane toime. Kõige aktiivsem aine sellest rühmast (6d) 
vähendas (50 µM kontsentratsioonil) VLP-de infektsioonilisust kuni 55%. 
Lähtudes ühendite struktuurist oletati, et need ained toimivad NRTI-dena; selle 
oletuse kinnitamist takistas aga ühendite madal aktiivsus. Teine grupp ühendeid 
64 
 
koosnes kuuest bimorfoliinist ja nende derivaatidest. Ühelgi neist ühenditest 
olulist retroviirus-vastast aktiivsust ei tuvastatud. Selline tulemus oli võimali-
kest ka kõige tõenäoliseim, sest sellise struktuuriga ühendid ei saa HIV-d 
inhibeerida seni teadaolevate mehhanismide kaudu. Seega on antud töö näiteks 
“katse ja eksimuse” meetodi rakendamisest inhibiitorite otsingul. Sellised eks-
perimendid võivad küll viia põhimõtteliselt uudsete toimeainete ja mehha-
nismide avastamiseni, kuid edu saavutamise tõenäosus on madal. Kolmanda 
ainete grupi moodustasid kaheksateistkümmend uudset sahariidhüdrasooni. 
Neid aineid võib pidada mitte-tsükliliste nukleosiidide analoogideks. Üsna 
ootuspäraselt olid need ühendid madalama HIV-1 vastase aktiivsusega, kui esi-
messe gruppi kuuluvad ained: kõige aktiivsema aine (ühend number 6) inhi-
beeriv kontsentratsioon 50 (IC50) oli ≈400 µM. Ehkki neil ühenditel puudusid 
toksilised kõrvalmõjud muutis väga madal aktiivsus nende põhjalikuma uuri-
mise ebapraktiliseks. 
Kolmandaks eesmärgiks oli uurida alternatiivse lähenemise – ratsionaalse 
ravimidisaini – kasutamise võimalusi. Eelneva töö (García-Sosa et al., 2011) 
käigus in silico meetodil uuritud ühenditest valiti järgnevateks analüüsideks 
välja kuusteist keemilist ühendit. Meie ülesandeks oli eksperimentaalselt kind-
laks teha, kas need ained võiksid toimida NNRTI-dena. Läbiviidud katsed näi-
tasid, et vaid üks ühend (number 8) kuueteistkümnest omas retroviirus-vastast 
toimet. Ehkki selle ühendi aktiivsus oli madal võimaldas selline tulemus alga-
tada ühendile 8 sarnaste ühendite uurimise. Selle töö käigus leidsime kaks uut 
HIV-1 inhibiitorit: ühendid number 18 ja 20. Ühend 20 osutus kõikidest meie 
laboris uuritud ainetest kõige tugevamaks HIV-1 inhibiitoriks: selle aktiivsus 
metsik-tüüpi viiruse suhtes oli võrreldav kliinilisel kasutusel oleva nevirapiini 
(NNRTI) aktiivsusega. Samas polnud ühelgi uuritud ühendil võimet oluliselt 
maha suruda NNRTI resistentsete pöördtranskriptaaside aktiivsust. Seega või-
maldas ravimite in silico ennustamine tõepoolest leida struktuuri, mis omas 
HIV-1-vastast toimet. Ehkki esialgsel kujul polnud see struktuur kaugeltki opti-
maalne võimaldas järgnev in silico analüüs kõrgema aktiivsusega ühendite 
kavandamist. Antud töö tõestab in silico eeluuringute rakendatavust akadee-
milises uurimistöö (kus pole reeglina võimalik läbi viia kõrge läbilaskevõimega 
skriiningut); samuti tõstab see esile in silico analüüsis saadud tulemuste eks-
perimentaalse kontrollimise tähtsust. 
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